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 ARB angiotensin receptor blocker
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 CrEDTA clear 51Chromium ethylenediamine tetraacetic acid clearance
 dU-prot 24 h urine protein excretion
 ESRF end stage renal failure
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9Abstract
IgA nephropathy (IgAN) is the most common primary glomerulo nephritis. 
It has been estimated that in one third of the patients the renal disease 
progresses, and they eventually need renal replacement therapy. IgAN is 
in most cases a slowly progressing disease, and the prediction of progres-
sion has been diffi cult, and also the results of studies have been confl ict-
ing. Henoch–Schönlein nephritis (HSN) is rare in adults, and prediction of 
the oucome is even more diffi cult than in IgAN.
The main interest in the present study was to determine the predictors 
of the outcome of IgAN and HSN in adults. Special attention was paid 
to patients with normal renal function at the time of diagnosing their 
renal disease. The second aim was to compare clinical and laboratory 
features and the outcome of IgAN in adults in four centres on three con-
tinents. The third aim was to measure urinary excretions of interleukin 
1ß (IL-1ß) and interleukin 1 receptor antagonist (IL-1ra) in patients with 
IgAN and HSN and the correlations of excretion of these substances with 
histopathological damage and clinical factors.
A large proportion of the patients diagnosed as having IgAN at the 
Division of Nephrology in Helsinki University Hospital had normal renal 
function and mild histopathological fi ndings. Four factors, (presence of 
hypertension, higher amounts of urinary erythrocytes, severe arteriolo-
sclerosis and a higher glomerular score) which independently predicted 
progression, were identifi ed in mild disease. It was shown that factors as-
sociated with outcome can be identifi ed even in mild cases of IgAN, and 
therefore indicate that early diagnosis of this disease is desirable. 
There was geographic variability in renal survival in patients with 
IgAN. When age, levels of renal function, proteinuria and blood pressure 
were taken into account, this study showed that the variability related 
mostly to lead-time bias and the inclusion of milder cases in centres with 
apparent good outcome. 
Similarly to fi ndings related to IgAN, the clinical and especially histo-
pathological fi ndings were milder than in other previous studies on adult 
HSN. HSN has been considered a systemic form of IgAN. In 18 % of the 
patients urinary abnormalities were detected prior to purpura, support-
ing overlapping of IgAN and HSN. HSN is rare in adults, and its outcome is 
unpredictable. Amount of proteinuria more than 0.4 g / 24 h was the only 
factor that was signifi cantly related to the progression of HSN. In a small 
group of patients with normal renal function at the time of diagnosis, 
the presence of hypertension and the level of renal function were found 
to be factors predicting outcome. 
Abstract
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In IgAN patients, IL-1ra excretion into urine was found to be decreased, 
compared with HSN patients and healthy controls. Patients with a high 
IL-1ra / IL-1β ratio had milder histopathological changes in renal biopsy 
than patients with a low / normal IL-1ra / IL-1β ratio. It was also found that 
the excretion of IL-1β and especially IL-1ra were signifi cantly higher in 
women. 
Abstract
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Introduction 
IgA nephropathy (IgAN) was fi rst described in 1968 (Berger and Hinglais 
1968). It is the most common form of primary glomerulonephritis. Most 
of the patients are in their 3rd or 4th decade of life at the time of diag-
nosis. Most of the patients have no symptoms and have been referred 
to renal biopsy on the basis of urinalysis taken for screening purposes, 
or investigation of some other condition. Since IgAN was fi rst described, 
it has become clear that it can not be considered a benign condition. It 
has been estimated that in about 30% of the patients the renal disease 
progresses and eventually need renal replacement therapy (Emancipa-
tor et al. 1985). In the past two decades, hundreds of studies have been 
published identifying numerous factors predicting the outcome in IgAN. 
The results of these studies have nevertheless been confl icting. IgAN is 
a slowly progressing disease, taking years, even decades, to progress to 
clinical renal failure. Being symptomless in most cases, the patient may 
have had the condition for a long time without knowing it. It depends 
on the renal biopsy policy at which time in the course of the disease the 
patient will be diagnosed, since the disease can not be diagnosed with-
out biopsy. The patients in the previous studies have therefore been in 
different stages of the disease, and this might partly explain the confl ict-
ing results. It has been suspected that there are true geographical dif-
ferences in the progression of the disease, and genetic markers of likely 
progression have been sought. 
Henoch–Schönlein purpura (HSP) was fi rst described in 1802 by Heber-
den (Heberden 1802). It was described as a combination of symptoms 
including purpuric rash, abdominal pain, bloody stools, arthralgia and 
macroscopic hematuria. Henoch (Henoch 1899) and Schönlein (Schön-
lein 1832) further described symtoms associated with renal disease. This 
disorder is called Henoch–Schönlein nephritis (HSN). In 1968, the same 
year in which Berger described IgAN, Urizar showed that patients with 
HSN have similar immunoglobulin deposits in renal biopsies as patients 
diagnosed to have IgAN (Urizar et al. 1968). HSN is usually diagnosed in 
children, but can be diagnosed for the fi rst time in adult age. Predicting 
the outcome of HSN in adults is even more diffi cult than in IgAN, since 
the condition is rare. The clinical fi ndings of IgAN are evident only in the 
kidneys. Despite this, IgAN and HSN share many clinical histological and 
immunological features. It has been suggested that HSN is a systemic 
form of IgAN (Davin et al. 2001). 
Introduction
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This study was conducted to evaluate the clinical and histopatho logical 
features and predictors of the outcome of IgAN and HSN diagnosed in 
one centre, and especially in patients with normal renal function at the 
time of renal biopsy. Furthermore, the study aims to evaluate whether 
there is a difference in the progression rates in four countries on three 
continents, and if so, can this be explained by differences in renal biopsy 
policy. 
Introduction
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IgA nephropathy 
Historical aspects and nomenclature
IgA nephropathy (IgAN) is the most common form of primary glomerulo-
nephritis, fi rst described in 1968 by Berger and Hinglais (Berger and Hing-
lais 1968, Berger et al. 1969), soon after the development of immuno-
histochemical techniques. They described a distinct form of primary 
glomerular disease in 55 patients with mesangial IgA, IgG and C3 deposits 
in renal biopsy specimens. The patients had persistent hematuria, mild 
proteinuria, 40% had episodes of macroscopic hematuria, and most of 
the patients displayed normal renal function.
Since the original description, there has been variation in termin ology. 
The names Berger´s disease (Levy et al. 1972), Berger´s mesangial IgA dis-
ease (Whitworth et al. 1976), IgA-IgG mesangial nephropathy (McEnery 
et al. 1973), IgA-associated glomerulonephritis (GN) (Lowance et al. 1973), 
isolated GN with mesangial IgA deposits (Sissons et al. 1975), IgA disease 
(Mathew et al. 1975), IgA mesangial deposits GN (Imbasciati et al. 1977), 
mesangial IgA GN (Yokoska et al. 1978), IgA mesangial GN (Zollinger and 
Mihatsch 1978), IgA-IgG nephropathy (Hood et al. 1981), IgA-mesangial 
nephropathy (D’Amico et al. 1981), mesangial IgA-nephritis (Sinniah et 
al. 1981), IgA nephritis (Shigematsu et al. 1982), mesangial IgA-associ-
ated nephropathy (Nicholls et al. 1984) and IgA GN (Nagy et al. 1979, 
Mustonen 1984a) have been used. The term IgA nephropathy has been 
used since 1974 (McCoy et al. 1974) and it has gained wide acceptance 
and is also used in this thesis.
Diagnosis 
IgAN is diagnosed by renal biopsy and the diagnosis is based on immuno-
fl uorescent microscopic fi ndings. The presence of glomerular predomin-
ant immunoglobulin A (IgA) deposits in immunofl uorescence staining is 
accepted as the diagnostic criterion for IgAN (Berger et al. 1969, D’Amico 
et al. 1981, Jennette 1988, Tomino 1999). 
Differential diagnosis
In addition to IgAN, glomerular mesangial deposits of IgA can be ob-
served in the nephritis associated with systemic lupus erythematosus 
(SLE). SLE and IgAN are usually easily recognized on the basis of clin ical 
and serological features. Henoch–Schönlein nephritis (HSN) and IgAN 
share identical histopathologiacal fi ndings (Fogazzi and Sheerin 1996, 
IgA nephropathy
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Tomino 1999, Davin et al. 2001) and HSN is considered to be a systemic 
form of IgAN. IgAN associated with chronic liver disease (especially al-
cohol-induced) is considered a secondary form of IgAN. Some authors 
have designated IgAN associated with several other conditions also as 
secondary IgAN. Among the best characterized associations are those 
with rheumatoid arthritis, ankylosing spondylitis, celiac disease, Reiter´s 
syndrome and viral diseases, particularly human immunodefi ciency virus 
(HIV) infection and hepatitis B (Mustonen 1984b, Floege and Feehally 
2000). This thesis deals with primary IgAN.
Histopathology
Immunofl uorescence
Mesangial IgA deposits (Figure 1) are diagnostic for IgAN and are paral-
leled by electron-dense deposits of the same distribution in electron 
micro scopy. There may be co-deposits of complement component 3 
(C3), immunoglobulin G (IgG), and less commonly of immunoglobulin 
M (IgM). There are no generally accepted precise criteria for making a 
patho logic diagnosis of IgAN. Most clinicopathologic studies of IgAN re-
quire glomerular immunostaining for IgA to be predominant over the 
staining for other immunoglobulins (Jennette 1988).
Figure 1 Immunofl uorescence fi nding of a glomerulus with IgAN showing typical 
intense mesangial staining for IgA.
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Light microscopy
The light microscopic fi ndings range from minimal changes to seg-
mental or diffuse mesangial hypercellularity (Figure 2) and necrotizing 
and crescentic GN. Advancing glomerulosclerosis with tubular atrophy 
and interstitial fi brosis are similar to other chronic glomerular diseases 
(Lee et al. 1982, Haas 1997, Floege and Feehally 2000). In addition to 
the glomerular alterations, a variety of tubulointerstitial and vascular 
changes may be identifi ed in patients with IgAN, including interstitial 
fi brosis tubular atrophy, interstitial infl ammation, arteriolosclerosis, or 
red cell casts and proteinaceous casts within the tubules. These features 
may be seen in progressive renal disease of any cause (Jennette 1988, 
Radford et al. 1996, Donadio and Grande 2002a). There is no uniform 
grading system for histopathological fi ndings in IgAN. The pathologic 
classifi cations used have been called lumped or split systems (Wyatt et al. 
1997, D’Amico 2004). The fi rst ones assess the overall severity of lesions 
based on the concomitant evaluation of the lesions found in the vari-
ous compartments (Lee et al. 2005). The most used lumped systems are 
those of Lee (Lee et al. 1982) and Haas (Haas 1997). The classifi cations by 
Figure 2 Light microscopy fi nding of a glomerulus with IgAN showing mesangial cell 
proliferation and matrix increase and adhesions to the Bowman capsule (arrows).
IgA nephropathy
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Haas and Lee have been used in clinicopathological studies (Bartosik et 
al. 2001) but most investigators have used the split systems (Droz et al. 
1984, Rekola et al. 1989, Bogenschutz et al. 1990, Alamartine et al. 1991, 
Packham et al. 1996, Koyama et al. 1997, Daniel et al. 2000, Donadio and 
Grande 2002b, Li et al. 2002), which use the semiquantitative severity 
grading of the various lesions and allow detailed analysis of glomeruli, 
tubules, interstitium and vessels. 
Clinical features 
There are no specifi c symptoms of IgAN. The clinical onset of IgAN is usu-
ally insidious. In the early stages of the disease, IgAN may often be sus-
pected only by routine screening or investigation of some other condi-
tion, and renal disease is therefore often discovered by chance. However, 
20–60% of the patients experience episode(s) of macroscopic hematuria 
which is often closely associated with respiratory tract infection (D’Amico 
1988, D’Amico 2004). The frequency of the episodes of macroscopic hema-
turia decreases with advancing age and is rarely seen after the age 40 
(Droz et al. 1984, Nicholls et al. 1984, Floege and Feehally 2000). Within 
the same age ranges the frequency of patients experiencing macroscopic 
hematuria varies greatly in different countries (D’Amico et al. 1985, 
Schena 1990) and depends on renal biopsy indications. It is less common 
in medical centres where patients with isolated microscopic hematuria 
undergo renal biopsy (D’Amico 1988). The presenting clinical sign in the 
remaining patients is microscopic hematuria associated with proteinuria, 
which, however, is usually mild or even absent (D’Amico 2004). Micro-
scopic hematuria has been considered to be an essential clinical fi nding 
in IgAN by some investigators (Tomino 1999). It can be either inter mittent 
or persistent (D’Amico 1988). Isolated proteinuria has been reported to 
be rare (2–4%) (D’Amico et al. 1984, Nicholls et al. 1984, Rodicio 1984), 
but in a few series (Mina and Murphy 1985, Katafuchi et al. 1998, Li et al. 
2002) a substantial proportion of the patients (9–23%) have presented 
with isolated proteinuria. Nephrotic syndrome is not a common fi nding. 
In most studies it is present in less than 10% of the patients (Clarkson et 
al. 1977, Woo et al. 1986, D’Amico 1988, Floege and Feehally 2000), but 
has been reported at diagnosis in 15% of the patients (Lai et al. 1988).
The frequency of impaired renal function at the time of diagnosis of 
IgAN has varied from 2% (Alamartine et al. 1991) to 59% (Radford et al. 
1996). Acute renal insuffi ciency is uncommon and occurs in only 5% of 
the cases. Acute renal insuffi ciecy is most often associated with bouts of 
macroscopic hematuria and can be due to crescentic IgAN (D’Amico et 
al. 1985, Floege and Feehally 2000). Hypertension is a common fi nding 
in IgAN patients, considering the age of the patients. 20–60% of the pa-
tients have been found to be hypertensive at the time of diagnosis of 
IgAN (D’Amico et al. 1984, Beukhof et al. 1986, Gallo et al. 1988, Lai et al. 
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1988, Bogenschutz et al. 1990, Rekola et al. 1990, Alamartine et al. 1991, 
Johnston et al. 1992, Frimat et al. 1997, Syrjanen et al. 2000b). Some pa-
tients present with malign hypertension together with urinary abnormal-
ities and renal insuffi ciency (Clarkson et al. 1977, Sinniah et al. 1981).
Epidemiology
IgAN is most commonly diagnosed in the third and fourth decades of life 
in adults, but can occur at any age (Droz et al. 1984, Rodicio 1984, Wyatt 
et al. 1984, Mina and Murphy 1985, D’Amico 1987, Caillette et al. 1993, 
Hogg et al. 1994, Ibels and Gyory 1994, Frimat et al. 1996, Radford et 
al. 1996, Donadio and Grande 2002c). More males than females are af-
fected. Worldwide the overall male / female ratio has been reported to be 
2 :1, varying from 1: 4 in Hong Kong to 6 :1 in North America (Colasanti et 
al. 1984, Schena 1990, To et al. 2000). 
The prevalence of IgAN is unknown since the disease may remain un-
detected. It may affect up to 1.3% of the population (Varis et al. 1993). 
IgAN is the main cause of end-stage renal failure (ESRF) in patients with 
primary glomerular disease (Levy and Berger 1988, Maisonneuve et al. 
2000). The prevalence rates are mostly expressed as a percentage of 
a total series of renal biopsies, and are highest in Asia, Australia and 
Finland (20–40%), lowest in Brazil, Peru, the United Kingdom, Canada 
and the United States (1–10%) (Colasanti et al. 1984, Mustonen 1984a, 
D’Amico 1987, Julian et al. 1988, Levy and Berger 1988, Habib et al. 1994, 
Ibels and Gyory 1994, Mazzarolo Cruz et al. 1996, Donadio and Grande 
2002a, Hall et al. 2004). In a recent study from China reporting the ana-
lysis of 13 519 renal biopsies, IgAN was diagnosed in 31% of the patients 
(Li and Liu 2004). IgAN is rare in blacks both in the United States and in 
Africa (Galla et al. 1985, Jennette et al. 1985).
Pathogenesis 
IgAN is considered to be an immune-complex-mediated glomerulo-
nephritis (Emancipator and Lamm 1989, Rantala et al. 2001). However, 
no specifi c antigen associated with IgAN has been identifi ed. There is 
strong support for the notion that IgAN is a systemic disease. Histologic 
evidence of recurrent IgAN is observed in 20–40% of patients who re-
ceive renal allografts (Ponticelli et al. 2001, Floege 2004). When a kidney 
from a donor with asymptomatic IgAN is transplanted into a recipient 
with ESRF due to a disease other than IgAN, the deposits in the donor 
rapidly disappear (Koselj et al. 1997).
IgA system 
Humans produce two isotype subclasses of IgA: IgA1 and IgA2. Mono-
meric IgA is joined by bridgin protein, J-chain, to form dimers or higher 
polymers, pIgA. Plasma cells associated with the gastrointestinal and 
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respiratory tracts produce both subclasses, whereas plasma cells in the 
bone marrow, lymph nodes, and spleen produce predominantly IgA1 
(Mestecky et al. 1986). The glomerular deposits of IgA in IgAN are ex-
clusively pIgA1 (Lomax-Smith et al. 1983). It has been suggested that 
IgAN results from hyperactivity of the mucosal immune system (Bene and 
Faure 1988). However, mucosal immunity, which is in part directed by 
IgA, is decreased in patients with IgAN (Feehally and Allen 1999a). In 
some patients with IgAN, the production of pIgA1 in the bone marrow 
is increased and may be responsible for the observed increase in serum 
IgA1 levels (Galla 1995, Harper et al. 1996). Furthermore, there is a re-
duced mucosal IgA response to mucosal immunization (de Fijter et al. 
1996) and an enhanced systemic pIgA response to systemic immuniza-
tion (Layward et al. 1992). However, increased production of IgA is not 
enough to cause IgAN. In patients with conditions in which serum IgA 
levels are incresed, for example in IgA-secreting myelomas and HIV, IgAN 
is found only rarely (Kilgore et al. 1985, Bene et al. 1991). IgA1 is a heav-
ily glycosylated molecule. Sugars are attached to proteins through two 
types of linkages. N-linked sugars are common in circulating proteins. 
O-linked sugars are widespread in cell surface proteins, but are common 
in circulating proteins as well. A unique feature of IgA1 is the presence 
of multiple O-glycosylation sites within the hinge region (Figure 3a). O-
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Figure 3a Hinge region of human IgA1 molecule. The O-glycans are linked to serine 
and/or threonine residues (Feehally and Allen 1999b).
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glycans are sugars in which N-acetylgalactosamine (GalNAc) is O-linked 
to serine or threonine (Figure 3b). (Allen et al. 1995, Mestecky et al. 1995, 
Feehally and Allen 1999b, Coppo and Amore 2004). 
Recent studies have shown that there is a defect in galactosylation 
of IgA1 both in serum and in IgA1 eluted from nephrectomy specimens 
obtained from patients with IgAN (Mestecky et al. 1993, Tomana et al. 
1997, Allen and Feehally 2000). Mesangial cells have a better ability to 
bind undergalactosylated IgA-containing immunocomplexes of patients 
with IgAN as compared with circulating immunocomplexes of healthy 
controls (Novak et al. 2002). Furthermore, undergalactosylated IgA1 
inter acts with C3 (Nikolova et al. 1994). Hepatic clearance of IgA1 is de-
creased in IgAN patients (Roccatello et al. 1993), probably due to altered 
O-glycolysation of IgA1, since the principal site of IgA catabolism is the 
asialoglycoprotein receptor in liver, which recognizes terminal galactose 
residues (Tomana et al. 1988).
In patients with IgAN, glycolysation abnormalities in the hinge region 
sugars of circulating IgA1 can lead to the formation of macromolecular 
complexes by self-aggregation of IgA1 or exposure of a neoantigen that 
is recognized by naturally occurring circulating IgA1 or IgG antibodies. 
These IgA1 complexes may favor mesangial deposition or initiation of 
glomerular infl ammatory processes (Allen 1995). The ensuing infl amma-
tory response often includes the proliferation of mesangial cells and the 
synthesis of exessive extracellular matrix. This process frequently culmin-
ates in progressive glomerular and interstitial scarring and renal in suffi -
ciency (Julian and Novak 2004).
Figure 3b The four possible structures (A–D) of O-glycans depending on galacto-
sylation and sialylation of GalNAc (Feehally and Allen 1999b).
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Cytokines and growth factors 
IgA1-deposits in the glomerulus are associated with infl ammation. Sev-
eral growth factors and cytokines, such as platelet-derived growth factor 
(PDGF), transforming growth factor β (TGFβ), interleukin 6 (IL-6), inter-
leukin 1 (IL-1), tumor necrosis factor α (TNFα) among many others, have 
an important pathogenetic role in IgAN as in other glomerulonephritides 
(Wardle 1991b, Abboud 1993, Ballardie et al. 1994). 
IL-1 is one of the most powerful moderators of infl ammation. It has 
been implicated in infl ammation associated with arthritis, colitis, athero-
sclerotic plaques, and in Henoch–Schönlein purpura (Dinarello and Wolff 
1993, Besbas et al. 1997). IL-1 is closely involved in the development of 
mesangial cell proliferation (Chen et al. 1995) and extracellular matrix 
production (Border and Noble 1993). In IgAN, IL-1 has been shown to 
be produced locally in the glomeruli (Taniguchi et al. 1996) and by per-
ipheral blood mononuclear cells (Matsumoto 1991). Glomerular and 
inter stitial expression of IL-1 has been demonstrated in IgAN (Yoshioka 
et al. 1993, Taniguchi et al. 1996). IL-1β activity has also been reported to 
be high in urine from patients with IgAN and HSN (Wu et al. 1996) and it 
has been suggested to play a role in the pathogenesis of HSN (Amoli et 
al. 2004). Interleukin 1 receptor antagonist (IL-1ra) and IL-1 are produced 
by monocytes / macrophages and polymorphonuclear cells in response to 
an identical stimulus. IL-1ra specifi cally inhibits IL-1 activity by competing 
for receptor binding, and is one of the most powerful endogenous anti-
infl amma tory agents. IL-1ra has been found to suppress IgAN in mice 
(Chen et al. 1997). IL-1ra has also been used effectively in the treatment 
of experimental animals with antibody-mediated glomerulonephritis 
(Lan et al. 1995). The results of studies on IL-1ra gene polymorphism 
have also demonstrated the importance of IL-1ra in HSN and IgAN. An 
increased rate of IL1RN*2 carriage was recently found in IgAN patients 
with macro scopic hematuria and in HSN patients. It was suggested that 
IL1RN*2 constitutes a genetic link between IgAN and HSN (Liu et al. 
1997). In another study the long-term survival rate among IgAN patients 
was shown to be lowest in those carrying IL1RN*2 (Shu et al. 2000). The 
results of these studies did not indicate what role, if any, IL1RN*2 plays in 
relation to IL-1ra levels in serum or urine.
IL-6 promotes proliferation of mesangial cells and synthesis of extra-
cellular matrix (Ruef et al. 1990). IL-6 has been reported to be involved in 
the proliferation of mesangial cells in IgAN (Ballardie et al. 1545, Horii et 
al. 1989, Iwano et al. 1992, Yoshioka et al. 1993, Grandaliano et al. 1996, 
Taniguchi et al. 1996, Taniguchi et al. 1999). In several studies urinary IL-6 
concentrations have been found to be more abundant in patients with 
IgA nephropathy (Horii et al. 1989, Tomino et al. 1991, Yoshioka et al. 
1993, Nakamura et al. 1995, Grandaliano et al. 1996). 
TGF-β is a potent regulator of immune systems and infl ammatory pro-
cesses, functioning as an endogenous immunosuppressor, and it is essen-
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tial for maintaining normal immune functions (Kitamura and Suto 1997). 
TGF-β is an inhibitor of mitogenesis in glomerular cells and a major con-
tributor to glomerular sclerosis and interstitial fi brosis (Border and Noble 
1993). The role of TGF-β in pathogenesis of IgAN has been suggested by 
several investigators (Niemir et al. 1995, Sakai et al. 1995, Murakami et 
al. 1997, Rastaldi et al. 1998). 
TNF-α has been implicated in the pathogenesis of glomerular injury 
(Noble et al. 1990, Tipping et al. 1991, Wardle 1991b, Wardle 1991a) and 
the progression of chronic glomerulonephritis (Baud et al. 1992, Meulders 
et al. 1992, Ozen et al. 1994, Baud and Ardaillou 1995). The effects of 
TNF on mesangial, endothelial, epithelial cells as well as on macro phages 
have been described, and these effects may mediate infl ammation in 
glomerulonephritis (Wardle 1991b, Wardle 1991a, Ardaillou and Baud 
1996). Previous investigations on TNF-α in IgAN have come up with con-
troversial results. Yoshioka et al have demonstrated TNF-α expression in 
IgAN, but TNF-α was not detected in any of the urine samples in their 
study. Neither did Tesar et al.(Tesar et al. 1998) fi nd any abnormal urinary 
TNF-alpha excretion in their IgAN patients. However, in one study (Wu et 
al. 1996) IgAN patients had signifi cantly more often urinary TNF-α activ-
ity than did controls. 
Role of genetics
There are genetic components in the pathogenesis of IgAN. Some rare 
familial forms of IgAN have been found (Julian et al. 1985, Egido et al. 
1987, Schena et al. 1990). Elevated serum IgA levels and overproduction 
of IgA by cultured peripheral blood B lymphocytes have been found in 
unaffected family members of patients with IgAN (Schena et al. 1993). 
However, population studies have failed to show any association of IgAN 
with any single genetic marker. This suggests that IgAN does not have 
classic Mendelian inheritance attributable to a single gene locus. IgAN 
rather seems to be a complex polygenic disease (Barratt et al. 2004). In a 
genome-wide analysis of linkage in 30 multiplex IgAN kindreds, a linkage 
of IgAN to 6q22–23 was demonstrated. Linkage, however, could only be 
demonstrated using a dominant mode of inheritance with incomplete 
penetrance and locus heterogeneity (Gharavi et al. 2000, Barratt et al. 
2004). The role of this IgAN1 gene still remains uncertain because its 
identity and function have not yet been clarifi ed. Though no single IgAN 
gene has been identifi ed, it has been speculated that individuals with 
IgAN must have an IgAN genotype / fenotype, a constellation of features 
representing a composition of all genetic loci contributing to the devel-
opment of IgAN and including genes infl uencing IgA deposition, genes 
controlling the mesangial infl ammatory response and other genes modi-
fying progression of renal disease, thus determining whether mesangial 
IgA is benign or initiates GN, and even the degree of renal damage (Bar-
ratt et al. 2004). 
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Outcome and factors associated with prognosis
Rate of progression
There are numerous studies on IgAN with a signifi cant number of cases 
showing progression to ESRF (Croker et al. 1983, Droz et al. 1984, Feiner 
et al. 1984, Nicholls et al. 1984, Rodicio 1984, D’Amico et al. 1985, Musto-
nen et al. 1985, Beukhof et al. 1986, Clarkson et al. 1987, Velo et al. 1987, 
Lai et al. 1988, Rekola et al. 1989, Bogenschutz et al. 1990, Alamartine et 
al. 1991, Johnston et al. 1992, Katafuchi et al. 1994, Radford et al. 1996, 
Frimat et al. 1997, Haas 1997, Ibels et al. 1997, Koyama et al. 1997, Nieu-
whof et al. 1998, Daniel et al. 2000, Syrjanen et al. 2000b, Bartosik et al. 
2001, Donadio and Grande 2002b, Li et al. 2002). There is huge variability 
in the clinical course. Emancipator et al. (Emancipator et al. 1985) re-
viewed 34 studies, published before 1985 (2317 patients), and concluded 
that IgAN had mostly an indolent course, with 20–50% of the patients 
developing ESRF in a period of 20 years. A rapidly progressive crescentic 
form of IgAN does exist, however, but is seen in only less than 1% of the 
patients (D’Amico et al. 1985). The actuarial renal survival at 10 years 
varies from as poor as 57% in Canada (Bartosik et al. 2001) to as good as 
94% in France (Alamartine et al. 1991). In most studies renal survival at 
10 years has been 81–87% (D’Amico 2004). Children have usually been 
considered to have a better prognosis than adults (Wyatt et al. 1984, Ku-
sumoto et al. 1987, Yaguchi et al. 1989, Hogg et al. 1994), but in a study 
of Wyatt et al. on 103 patients diagnosed before the age of 18 years, the 
outcome appeared to be as serious as that reported in adult patients: 
predicted kidney survival at 10 years was 82% (Wyatt et al. 1995).
Several studies have been conducted in different geographical regions 
on large, relatively nonselected cohorts of mainly adult patients, and the 
actuarial renal survival rate at 10 years has been calculated (Droz et al. 
1984, Nicholls et al. 1984, Beukhof et al. 1986, D’Amico et al. 1986, Woo 
et al. 1986, Noel et al. 1987, Velo et al. 1987, Rekola et al. 1989, Bogen-
schutz et al. 1990, Alamartine et al. 1991, Johnston et al. 1992, Ibels and 
Gyory 1994, Katafuchi et al. 1994, Miyazaki et al. 1996, Radford et al. 
1996, Haas 1997, Koyama et al. 1997, Usui et al. 2001). Survival rate at 
10 years has varied from 67–94% in these studies, as referred recently by 
D´Amico (D’Amico 2000, D’Amico 2004).
It has been estimated that 4–23% of patients will have a complete 
clinical remission of IgAN (Nicholls et al. 1984, Costa et al. 1987, D’Amico 
et al. 1987, Bogenschutz et al. 1990, Johnston et al. 1992, Radford et al. 
1996, Ibels et al. 1997, Usui et al. 2001, Donadio and Grande 2002a)
Factors affecting outcome
In the past two decades, hundreds of papers have been published identify-
ing factors predicting the outcome in IgAN. Most studies have identifi ed 
the following clinical and histopathological parameters as predictors of 
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outcome: (1) high level of proteinuria (Beukhof et al. 1986, D’Amico et al. 
1986, Rekola et al. 1989, Alamartine et al. 1991, Frimat et al. 1997, Ibels 
et al. 1997), (2) existence of hypertension (Beukhof et al. 1986, Alamar-
tine et al. 1991), (3) poor renal function (Beukhof et al. 1986, Johnston et 
al. 1992, Radford et al. 1996, Frimat et al. 1997, Ibels et al. 1997), (4) ab-
sence of episodes of macroscopic hematuria (Beukhof et al. 1986, Frimat 
et al. 1997), (5) male sex (Frimat et al. 1997), (6) age (Radford et al. 1996), 
(7) the extent of microscopic hematuria (Beukhof et al. 1986), (8) levels of 
serum urate (Syrjanen et al. 2000b), (9) levels of serum triglycerides (Syr-
janen et al. 2000b), (10) obesity (Bonnet et al. 2001), (11) smoking (Orth 
et al. 1998), (12) various histopathological fi ndings, mainly glomerular 
alterations (D’Amico et al. 1986, Radford et al. 1996, Ibels et al. 1997, 
Katafuchi et al. 1998) but also tubulointerstitial changes (Bogenschutz et 
al. 1990). The total histopathological score (Rekola et al. 1989, Alamar-
tine et al. 1991) has also been found to be related to progression.
D´Amico has evaluated these studies and analyzed the results of the 
most valid ones (D’Amico 2000, D’Amico 2004), based on following re-
quirements: (1) large cohorts of patients as nonselected as possible, 
(2) defi nite histological and clinical criteria for the diagnosis and out-
come of the idiopathic type of disease, (3) a reasonably complete and 
prologned follow-up and (4) accurate statistical evaluation. In the careful 
evaluation of the selected papers, it was concluded that the strongest 
predictors of an unfavorable outcome in IgAN are: elevated serum cre-
atinine level at presentation, severe proteinuria at presentation and / or 
follow-up, hypertension, widespread global and / or segmental glomerulo-
sclerosis and / or marked tubulointerstitial lesions or a high glomerular 
and tubulointerstitial score of lesions. It should be noted that most of 
the papers evaluated by D´Amico have included children as well (Droz 
et al. 1984, Nicholls et al. 1984, D’Amico et al. 1985, D’Amico et al. 1986, 
Rekola et al. 1989, Bogenschutz et al. 1990, Alamartine et al. 1991, Ibels 
et al. 1997, Katafuchi et al. 1998, Syrjanen et al. 2000b, D’Amico 2004).
So far there are only two studies on adults only (age > 16 yrs), in which 
both clinical and histopathological predictors of progression have been 
evaluated by multivariate analysis (Radford et al. 1996, Li et al. 2002). 
The study of Radford et al. included 148 patients who were followed for 
more than six years on average. Independent predictive factors for an 
unfavorable outcome were: (1) impaired renal function, (2) young age at 
the time of diagnosis and (3) higher glomerular score in histopathology. 
Li et al. in their study followed 168 patients from Hong Kong for over 7 
years (mean), and showed that independent factors affecting outcome 
were: (1) presence of hypertension, (2) family history of hypertension, 
(3) s-creatinine > 120 µmol / l and (4) proteinuria > 1 g / 24 h at the time of 
diagnosis as well as (5) a higher level of histopathological grading. 
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Treatment
Since the etiology of IgAN is still unknown, specifi c and effective treat-
ment is not yet available. The focus remains in reducing the amount of 
proteinuria to less than 0.5 g / day (Julian and Novak 2004) and blood 
pressure below 130 / 80 mmHg (Glassock 1999). In an attempt to slow the 
progression of IgAN and preserve renal function, several treatments, such 
as ACE inhibitors, corticosteroids, fi sh oil supplements and tonsillectomy 
are used in clinical practice. Carefully designed, randomized, prospective 
trials are still few.
Corticosteroids
Corticosteroids have been used in treating IgAN since the early 1980s. 
Since then several retrospective or uncontrolled studies have published 
(Mustonen et al. 1983, Kobayashi et al. 1988). The fi rst randomized trial 
(Lai et al. 1986) showed no signifi cant benefi cial effect on renal func-
tion. Pozzi et al. (1999) in their randomized, prospective, controlled two-
year trial observed a rapid decline in proteinuria in treated patients, and 
a slight but signifi cant positive effect on renal outcome in a fi ve-year 
extension study. They even showed that the 10-year renal survival was 
signifi cantly longer in steroid treated patients than in the control group 
(Pozzi et al. 2004). Two controlled trials of early corticosteroid treatment, 
as compared with antiplatelet treatment, demonstrated a signifi cant de-
crease in proteinuria, but no change in renal function (Shoji et al. 2000, 
Katafuchi et al. 2003). 
Angiotensin-converting enzyme (ACE) inhibitors 
and angiotensin II receptor blockers (ARB)
Inhibiting the renin-angiotensin system with ACE inhibitors reduces pro-
teinuria in IgAN (Remuzzi et al. 1991, Maschio et al. 1994, Hernandez et 
al. 1997, Perico et al. 1998). ACE inhibitors have been shown to reduce 
impairement of renal function in one study on 10 patients (Feriozzi et al. 
1989) and in one retrospective evaluation (Cattran et al. 1994). In a recent 
randomized, controlled study, Praga et al. (2003) compared ACE-inhibitor 
enalapril to other antihypertensive treatments, and found a signifi cant 
decrement in proteinuria and better renal outcome in the enalapril group 
(Praga et al. 2003). Also, a substantial number of patients (21%) in the 
REIN study had IgAN, and among the IgAN patients the relative risk for 
ESRD was reduced by 28% in the ramipril group (Dillon 2004).
ARBs and ACE inhibitors are equally effective in reducing the amount 
of proteinuria (Perico et al. 1998, Russo et al. 1999). Randomized stud-
ies, comparing the effects of ARBs and ACE inhibitors in IgAN, however, 
have not been published. In selected patients with IgAN, combination 
therapy with ACE inhibitors and angiotensin II receptor antagonists have 
demonstrated a greater antihypertensive and antiproteinuric effect than 
either drug alone (Russo et al. 1999). In a COOPERATIVE study where 
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ARB losartan and ACE inhibitor trandolapir and their combination were 
compared with conventional antihypertensive therapy, 336 patients with 
non-diabetic renal diseases were enrolled and 50% of the patients had 
IgAN. The results showed that these two drugs had an equally protective 
effect on renal function. The study also indicated that thecombination 
therapy preserved renal function better than either drug alone (Nakao 
et al. 2003). 
Other therapies
The theoretical background for the use of fi sh oil in IgAN is not well 
defi ned. Fish oils are important sources of omega-3-polyunsaturated 
fatty acids. It has been suggested that these compounds have an anti-
infl ammatory effect, improve blood pressure and lower serum tri glycer-
ide levels. They also alter cytokine and eicosanoid production and de-
crease platelet aggregation (Donadio 1991, Donadio and Grande 2004). 
The studies by Bennet et al. (1989) and Petterson et al. (1994) found no 
benefi cial effect of fi sh oils. In contrast, Donadio et al. (Donadio et al. 
1999, Donadio and Grande 2004) found a signifi cant benefi cial effect 
of fi sh oil on renal function in a two-year follow-up. The patients in the 
study of Donadio had more impaired renal function than the patients in 
the studies of Bennet and Petterson. However, as demonstrated by two 
meta-analyses (Dillon 1997, Strippoli et al. 2003), the overall results of 
fi sh oil therapy in IgAN are still controversial.
The role of tonsillectomy in IgAN remains inconclusive. Removal of 
tonsils reduces serum IgA levels, circulating immune complexes, and may 
reduce the amount of microscopic hematuria and proteinuria (Masuda 
et al. 1988, Tamura et al. 1993, Akagi et al. 1999, Hotta et al. 2001). 
However, there is little data on the effect of tonsillectomy on long-term 
renal survival. In a recent retrospective study from Japan (Xie et al. 1999), 
tonsillectomy was associated with better renal outcome on multivariate 
analysis. 
Anticoagulant and antiplatelet therapy have long been used in IgAN. 
Most studies have been uncontrolled, small in size and with a short 
follow-up, and in most studies other treatments like corticosteroids or 
cyto toxic agents have been used (Woo et al. 1987, Walker et al. 1990). Lee 
et al. used a combination of dipyramidole and warfarin in a randomized 
controlled trial with a follow-up of three years in patients with impaired 
renal function (142–265 µmol / l) (Lee et al. 1997), but the number of pa-
tients was small, only 11 in the treatment group and 10 in the control 
group. Renal function remained stable in the treatment group but de-
terior ated in the control group.
Numerous other approaches to the therapy of IgAN have been de-
scribed, including treatment with cyclophosphamide (Tumlin and Henni-
gar 2004), cyclosporine (Chabova et al. 2000), azathioprine (Goumenos et 
al. 2003), fl uvastatin (Buemi et al. 2000), mizoribine, danazol, phenytoin, 
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gluten-free and low-antigen-content diets, intravenous immunoglobu-
lins, plasmapheresis, and doxycycline (Glassock 1999). These therapies 
have shown minimal, if any, long-term benefi t. Recently, a controlled, 
randomized study of 34 IgAN patients treated with mycophenolate 
mofetil (MMF) was published (Maes et al. 2003) but no benefi cial effect 
of three-year MMF treatment could be demonstrated. 
Transplantation 
Renal transplantation is a good option for the treatment of IgAN, since 
patients with IgAN are mostly otherwise healthy young adults. The sur-
vival of both patients and renal allografts is good, when compared with 
patients with other renal diseases (Andresdottir et al. 2001, Ponticelli et 
al. 2001). The outcome of renal transplantation in patients with IgAN may 
be affected by recurrence of the original disease. Berger et al. (Berger 
1984, Berger 1988) diagnosed a histological recurrence of IgAN in ap-
proximately 50% of the patients on the basis of routine biopsies. There is 
great variability in the reported recurrence rates, varying from less than 
13% up to 53% of grafts fi ve years after transplantation (Frohnert et al. 
1994, Hartung et al. 1995, Frohnert et al. 1997, Bumgardner et al. 1998, 
Freese et al. 1999, Ponticelli et al. 2001, Wang et al. 2001). Higher recur-
rence rates are reported from centers performing serial biopsies of the 
renal allografts in all recipients (Berger 1984, Frohnert et al. 1997, Floege 
2004). The number of recurrences has been found to be the same in ca-
daveric kidneys and kidneys from living related donors (Frohnert et al. 
1994, Frohnert et al. 1997). Graft loss due to recurrence of IgAN is rare, 
however, being 4–12% of the grafts (Odum et al. 1994, Bumgardner et al. 
1998, Ponticelli et al. 2001). Contemporary immunosuppression regimens 
have not altered the recurrence rates of IgAN (Floege et al. 1998).
Henoch–Schönlein nephritis
Historical aspects and nomenclature
Heberden (Heberden 1802) was the fi rst to describe the association of 
macroscopic hematuria with a purpuric rash, abdominal pain, bloody 
stools and arthralgia. Schönlein (Schönlein 1832) reported the association 
of arthritis with purpura in the lower limbs in 1832 and Henoch recog-
nized gastrointestinal and renal involvement of this sydrome in 1899 
(Henoch 1899) in four children. Urizar et al. (Urizar et al. 1968) showed 
similar IgA deposits in the renal biopsies of patients with HSP-associated 
nephritis in the same year as Berger and Hinglais characterized IgAN.
Since the original description of the disease, there has been varia-
tion in terminology. For Henoch–Schönlein purpura-associated nephritis, 
the following terms have been used in the literature: Scönlein–Henoch 
neph ritis (Bar-On and Rosenmann 1972, Meadow et al. 1972, Fogazzi 
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et al. 1989, Emancipator 1992, Fogazzi and Sheerin 1996, Piette 1997), 
Henoch–Schönlein purpura nephritis (Niaudet et al. 1984, Rostoker et al. 
1998, Davin and Weening 2001), Henoch–Schönlein purpura glomerulo-
nephritis (Andreoli 1998), Henoch–Schönlein syndrome (Sinniah et al. 
1978, Weiss et al. 1978, Mihatsch et al. 1984, Meadow and Scott 1985, 
Roth et al. 1985) and Henoch–Schönlein nephritis (Kalowski and Kincaid-
Smith 1973, Koskimies et al. 1981, Yoshikawa et al. 1981, Lee et al. 1986, 
Faull et al. 1987, Williams et al. 1987, Goldstein et al. 1992, White 1994, 
Coppo et al. 1997, Ronkainen et al. 2002). In this thesis, the term Henoch–
Schönlein nephritis is used.
Diagnosis
In the early years, HSP was diagnosed on the basis of a typical clinical pic-
ture, and HSN as a nephritis associated with HSP. Only after the develop-
ment of immunohistochemical techniques, and the defi nition of IgAN, a 
defi nite diagnosis of HSN has been possible (Urizar et al. 1968, Davin and 
Weening 2001, Davin and Weening 2003). HSN is an IgA-mediated vascu-
litis in which the glomerular disease is indistinguishable from IgAN. IgAN 
seems to be a kidney-restricted form of HSP (Davin et al. 2001).
Two diagnostic classifi cations have been proposed for HSP. The defi n-
ition according to the American College of Rheumatology (Mills et al. 
1990) is based largely on clinical features, relying on the presence of 
two or more of the following characteristics: age 20 years or younger, 
palpable purpura, acute abdominal pain, and granylocytic infi ltration 
of arteriolar or venular walls. The Chapel Hill Conesensus Group defi nes 
HSP as a vasculitis with IgA-dominant immune deposits, affecting small 
vessels (i.e., capillaries, venules, arterioles) and typically involving skin, 
gut, and glomeruli, and associated with arthralgia or arthritis (Jennette 
et al. 1994). In this thesis, the latter defi nition is used, since the fi rst one 
excludes most adults and does not require immunohistochemical con fi rm-
ation.
Differential diagnosis
Cutaneous leukocytoclastic angiitis is a small vessel vasculitis that has 
similar clinical skin features as HSP, and can have IgA deposits in the ves-
sels, but has no systemic involvement. However, patients with cutaneous 
leukocytoclastic angiitis with IgA deposits are at greater risk for systemic 
immune complex-mediated vasculits than those with HSN (Jennette et 
al. 1994). Other conditions that might mimic HSN are cryoglobulinemic 
vasculitis, hypersensitivity vasculitis, microscopic polyangitis, polyarteritis 
nodosa, Wegener disease, and SLE. In hepatic diseases, purpura is usually 
associated with thrombocytopenia. The diagnosis of HSN by renal biopsy, 
with typical histopathological fi ndings of IgAN, combined with extra 
renal fi ndings of HSP usually make this renal disease easily dis tinguishable 
from the conditions mentioned above. In SLE, hepatic diseases, Wegener 
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granulomatosis and microscopic polyangitis, serological parameters can 
be used to help differentation. 
IgAN has been prescribed to predispose to HSP, and these two condi-
tions can be distinguished only by follow-up of extrarenal manifestations 
typical to HSN (Coppo et al. 1999, Pillebout et al. 2002). The existence of 
secondary forms of HSN is questionable. HSP has been reported to be as-
sociated with other conditions such as cancer, alcoholic liver disease and 
monoclonal IgA gammopathy. Furthermore, HSN has been described in 
association with hypersensitivity, and several drugs have been connected 
with the initiation of HSP and HSN, such as vancomycin, levodopa, acetyl-
salicylic acid and ciprofl oxacin (Davin et al. 2001). 
Histopathology
Histologically cutaneous HSP is a small vessel leukocytoclastic form of 
vascu litis. The presence of IgA as the predominant immunoreactant is 
considered fundamental to the diagnosis of HSP (Jennette 1988). Simi-
lar histopathological fi ndings have been reported in the digestive tract 
in HSP (Gunasekaran 1997). Patients with HSN have renal immuno histo-
logical fi ndings indistinguishable from those of IgAN (Urizar et al. 1968, 
Emanci pator 1992, Davin et al. 2001). At light microscopy, the renal 
biopsy fi ndings also resemble those of IgAN. Extracapillary proliferation 
is generally more prominent and frequent in HSN than in IgAN, in many 
cases, accounting for 20–30% of glomeruli (Scivittaro et al. 1993)
As in IgAN, there is no universally accepted grading system for histo-
patho logical fi ndings of renal biopsy. There are only a few studies with 
suffi ciently large materials to successfully use any grading system in 
adults. However, the classifi cation devised by the pathologists of the Inter-
national Society of Kidney Disease in Children (SPNS 1985), and modifi ca-
tions of this classifi cation (Lee et al. 1986, Emancipator 1992, Coppo et 
al. 1997) have been used widely. As in IgAN, semiquantitative grading 
systems have been used as well (Faull et al. 1987, Fogazzi et al. 1989). 
Clinical features
The characteristic clinical features of HSN include non-thrombocytopenic 
purpura, gastrointestinal disease, arthralgia / arthritis and glomerulo-
nephritis. Other organs, including the central nervous system, cardio-
pulmonary and musculosceletal systems are less commonly affected (An-
dreoli 1998). Palpable non-thrombocytopenic purpura is located mainly 
in the lower limbs and buttocks, but may have extensions to the trunk. 
Ulcerative, necrotizing lesions are not uncommon (Piette and Stone 
1989), and occur mainly in adults and older patients (Piette 1997, Pil-
lebout et al. 2002). Recurrences of purpura are common (Pillebout et 
al. 2002). Abdominal pain is usually mild and colicy, and bloody stools 
may be present. Gastrointestinal involvement can even be fatal in older 
patients (Cream et al. 1970, Pillebout et al. 2002). Arthralgia without arth-
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ritis locates mainly in the large joints of the legs (Coppo et al. 1999).
Although systemic disease and nephritis usually occur together, the 
renal involvement may either precede the systemic symptoms (Silverstein 
et al. 1994) or conversely appear after the systemic signs have resolved 
(Waldo 1988, Coppo et al. 1999, Pillebout et al. 2002). 
The clinical features in HSN resemble those in IgAN. Some 10% of the 
patients have episode(s) of macroscopic hematuria (Coppo et al. 1999, 
Pillebout et al. 2002). A history of a recent infection, usually upper res-
piratory or gastrointestinal infection, have been reported in up to 75% 
of the patients (Davin and Weening 1201). The rest of the patients have 
urinary abnormalities: microscopic hematuria and / or proteinuria with or 
without renal insuffi ciency. The proportion of patients presenting with 
nephritic (defi ned usually as hematuria, hypertension, renal insuffuciency 
and oliguria) or nephrotic syndrome has been estimated to be larger in 
HSN than in IgAN, 25% of the children (Goldstein et al. 1992) and 33% 
of the adults (Rieu and Noel 1999). However, as in IgAN, the number of 
patients having impaired renal function and severe urinary fi ndings at 
the time of diagnosis of HSN depends on renal biopsy indications. Hyper-
tension is a frequent fi nding: 22–36% of HSN patients have been hyper-
tensive at the time of diagnosis of HSN (Faull et al. 1987, Coppo et al. 
1999, Pillebout et al. 2002).
Epidemiology
Children are much more affected with HSP than adults, but the disease 
can occur at any age. The incidence of HSP is highest between 2 and 5 
years of life (White 1994, Piette 1997). It has been estimated that the 
incid ence for HSP in children is 14 per 100 000 per year (Stewart et al. 
1988) and that renal involvement occurs in 33% of the patients, account-
ing for 10–15% of glomerulonephritis (Rieu and Noel 1999). 
The epidemiological studies on HSP and on HSN, performed thus far, 
have not taken into account the presence of IgA deposits in tissues as a 
diagnostic criterion (Davin et al. 2001), and therefore all the percentages 
should be viewed with caution. In adults these fi gures are even more 
inaccurate, since HSP is rare in adults, and few studies have reported 
them. Garcia-Porrua reported urinary fi ndings in 10 out of 28 patients 
with HSP, and two had renal insuffi ciency (Garcia-Porrua et al. 2000). 
However, there was no histopathological confi rmation, and patients hav-
ing re mission of renal fi ndings at the end of follow-up were not classi-
fi ed as having renal involvement in this study. In another recent study by 
Tancrede-Bohin et al., evaluating 57 HSP patients, 13 exhibited biopsy-
proven HSN and an additional 15 had urinary fi ndings, thus 49% of all 
patients having renal involvement (Tancrede-Bohin et al. 1997). Further-
more, based on seven published studies on adults with HSP (Debray et al. 
1805, Bernhardt 1968, Cream et al. 1970, Bar-On and Rosenmann 1972, 
Michel et al. 1992, Blanco et al. 1997a, Tancrede-Bohin et al. 1997), Rieu 
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has estimated renal involvement during HSP is somewhat more frequent 
in adults than in children, 63% (Rieu and Noel 1999). As in IgAN, the sex 
ratio shows an increased frequency in males (Davin et al. 2001). Due to 
the rareness of HSN in adults, no differences in prevalence rates in differ-
ent countries can be estimated (Davin and Weening 2001). 
Pathogenesis
Since the defi nition of HSN has varied (Mills et al. 1990, Jennette et al. 
1994), and renal biopsy and immunohistochemical techniques to iden-
tify glomerular IgA deposits have not always been required to diagnose 
HSN, the patient populations have varied signifi cantly in the literature. 
Therefore, it is not surprising that the pathogenesis of HSP and HSN is 
still unknown. There is evidence that, like IgAN, it is an immune complex 
mediated disease (Levinsky and Barratt 1979, Casanueva et al. 1990). An 
association between upper respiratory and gastrointestinal infections 
and onset of HSP has frequently been demonstrated. However, no single 
agent or antigen has been associated with HSN.
It has been reported that a family member of a patient with HSP is 
at increased risk of developing IgAN or HSN. This suggests that genetic 
background or similar environmental factors may lead to the develop-
ment of both diseases (Levy 1989). Scattered case reports have described 
families including one member with IgAN and another with HSN, and 
this has even been described in twins (Waldo 1988, Davin et al. 2001). In 
addition, the histologic fi ndings of IgAN and HSN are indistinguishable, 
indicating that HSN is a systemic form of the same disease process (Wada 
et al. 2003). Furthermore, IgAN may be diagnosed several months before 
any extrarenal manifestations of HSP (Coppo et al. 1997, Rieu and Noel 
1999, Pillebout et al. 2002) 
Similar pathogenetic processes have been suggested to be present in 
HSN and IgAN. Allen et al. reported that the O-glycolysation of serum 
IgA1 is abnormal in adults and children with HSN, but not in persons with 
other types of glomerulonephritis (Allen 1998). Furthermore, IgA1 gly-
colysation was normal in children with HSP, but without any symptoms 
of renal involvement. No adult patients with HSP without renal involve-
ment were studied. However, the observation by Allen et al supports the 
role of under galactosylated IgA1 in the pathogenesis of HSN.
Cytokines and growth factors have probably as important patho-
genetic role in HSN, as in IgAN. Increased serum levels of TNFα, IL-6 and 
IL-1 have been detected in HSP (Besbas et al. 1997). Also, an increased 
rate of IL1RN*2 carriage was recently in HSN patients. It was suggested 
that IL1RN*2 constitutes a genetic link between IgAN and HSN (Liu et al. 
1997).
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Outcome and factors associated with prognosis of HSN 
Rate of progression 
The development of renal involvement is the most important factor af-
fecting outcome in HSP 
(Piette 1997, Tancrede-Bohin et al. 1997). Other symptoms of HSP have 
a strong tendency to disappear after weeks to months in both children 
and adults, although relapses of purpura episodes may occur (Piet te 1997). 
There are several pediatric studies with long follow-up times (Kaku et al. 
1998, Meadow et al. 1972, Koskimies et al. 1981, Yoshikawa et al. 1981, 
Goldstein et al. 1992, Coppo 1999, Saulsbury 1999). Goldstein (Goldstein 
et al. 1992) have showen that chronic renal failure can develop even af-
ter complete clinical remission of the condition. Similar studies on adults 
with HSN are scarce. In some studies on adults, no immuno fl uorescence 
method has been used (Bernhardt 1968, Bar-On and Rosenmann 1972), 
in other studies the numbers of patients were small and / or the follow-up 
times were short (Debray et al. 1805, Kalowski and Kincaid-Smith 1973, 
Sinniah et al. 1978, Lee et al. 1986, Faull et al. 1987, Fogazzi et al. 1989). 
Some of these studies were conducted primarily on patients with HSP; 
pathological urinary fi ndings were noted in only some of them, and renal 
biopsy was not undertaken in all such cases (Debray et al. 1805, Bernhardt 
1968, Cream et al. 1970, Bar-On and Rosenmann 1972, Tancrede-Bohin et 
al. 1997). Only two studies have been published on adult patients with 
HSN (Coppo et al. 1997, Pillebout et al. 2002) in which all cases were diag-
nosed by renal biopsy. Renal survival at 10 years after diagnosis varied 
from 75% (Coppo et al. 1997) to 81% (Pillebout et al. 2002). Both had 
unselected patient material, but neither included patients with isolated 
microscopic hematuria with normal renal function. In Coppo´s study 76% 
of adults had s-creatinine < 133 µmol / l and in Pillebout´s study 68% had 
Ccr > 60 ml / min. 
It is believed that adults with HSN have a worse prognosis than chil-
dren (Meadow 1978). However, recent long-term studies have suggested 
that the prognosis of children might be worse than originally thought 
(Goldstein et al. 1992, Ronkainen et al. 2002). In a study by Coppo et al. 
(Coppo et al. 1997) and Blanco et al. (Blanco et al. 1997b) renal survival 
was equal in children and adults: 75% at 10 years after diagnosis. Studies 
on adults with long follow-up periods have shown clinical remission rates 
of 20% (Pillebout et al. 2002) to 33% (Coppo et al. 1997).
Factors affecting outcome 
Since HSN in adults is rare, the factors affecting outcome are still largely 
unknown. In studies with small numbers of patients or short follow-up 
periods, the following factors at the time of diagnosis have been pro-
posed: severe histopathological fi ndings (Bar-On and Rosenmann 1972, 
Faull et al. 1987), higher percentage of crescents in renal biopsy (Bar-On 
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and Rosenmann 1972, Sinniah et al. 1978, Faull et al. 1987, Fogazzi et al. 
1989) and impairment of renal function (Bar-On and Rosenmann 1972).
In a study (Coppo et al. 1997) on 95 adults from 43 Italian clinics, and a 
mean follow-up of 4.8 years, the following factors affected the outcome 
in univariate analysis: (1) impairment of renal function, (2) proteinuria 
higher than 1.5 g / 24 h and (3) hypertension. Proteinuria served as an in-
dependent prognostic factor. Pillebout et al. (Pillebout et al. 2002) have 
reported a group of 250 adults with HSN from 11 clinics in France, with 
a mean follow-up of 14.8 years. In their study, (1) older age (> 50 yrs), 
(2) impaired renal function, (3) proteinuria > 1 g / 24 h, (4) presence of mac-
roscopic hematuria and (5) severe histopathological fi ndings were associ-
ated with severe outcome by univariate analysis. In multivariate analysis, 
(1) impaired renal function, (2) degree of proteinuria, and (3) the degree 
of interstitial fi brosis, percentage of sclerotic glomeruli, and presence of 
glomerular necrosis were associated with poor outcome.
Treatment
The therapies used are essentially the same as the ones used in IgAN. 
There are very few studies on the therapy of HSN, but all of them are 
on children, and have a relatively short follow-up. There is thus a lack 
of prospective, controlled studies. Corticosteroids are most widely used, 
often in combination with cytotoxic treatments and antiplatelet agents. 
(Saulsbury 1993, Oner et al. 1995, Iijima et al. 1998, Niaudet and Habib 
1998, Foster et al. 2000, Kawasaki et al. 2004). Recent studies in children 
with HSN have reported the successful use of cyclophosphamide (Tarshish 
et al. 2004), cyclosporine A (Ronkainen et al. 2003) and a combination 
therapy of corticosteroids and azathioprine (Bergstein et al. 1998). A re-
cent case report suggested the use of double-fi ltration plasmapheresis in 
adults with HSN (Chen et al. 2004)
In a retrospective study on adults with HSN, 56% of the patients were 
treated either by corticosteroids, cyclophoshamide or combination of 
these drugs (Pillebout et al. 2002). The effi cacy of corticosteroids and / or 
cyclophosphamide in reducing the incidence of severe renal insuffi ciency 
could not be demonstrated. It is worth noting that the most common 
causes of death were neoplasia (27% of deaths) and infections (16% of 
deaths). Patients dying of cancer were not treated more often with cyto-
toxic drugs, but eight of the 12 lethal infections were attributable to 
immunosuppressive treatment.
Transplantation 
Little is known about HSN after renal transplantation, as the numbers of 
patients included are small (Meulders et al. 1994, Haubitz et al. 1997). 
Andresdottier et al. analyzed separately the recurrence rates of HSN and 
IgAN patients. None of 9 HSN patients developed clinically evident recur-
rence of IgAN (HSN) during a mean follow-up of more than fi ve years 
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(Andresdottir et al. 2001). In the study of Pillebout et al. (Pillebout et al. 
2002), 12 patients received renal transplants, and none of them lost their 
graft because of recurrent disease. It has been estimated that the recur-
rence rates of clinically relevant IgAN in patients with HSN are similar to 
those reported in patients with primary IgAN (Floege 2004).
Differences between IgAN and HSN
Davin et al. (2001) have recently reviewed the literature relating to differ-
ences between the two diseases. Apart from the presence of extrarenal 
clinical signs in HSN, only a few differences between the two conditions 
have been found. IgAN occurs in children, but is most often diagnosed in 
adulthood. HSN, on the other hand, is mainly seen in childhood. There are 
no studies comparing the clinical and histopathological features of HSN 
and IgAN in large patient populations diagnosed in the same hospital 
and with the same renal biopsy indications. Therefore reliable compari-
sons between clinical features cannot be made. There is some evidence 
that necrosis, crescents and fi brin deposits are more common in HSN than 
in IgAN (Emancipator 1992). Hypersensitivity has been described in associ-
ation with HSN, and patients with HSN have had higher plasma IgE and 
eosinophil cationic protein levels than patients with IgAN. Furthermore, 
children with HSN present with nephrotic and nephritic syndrome more 
often than those with IgAN (Davin et al. 2001).
Differences between IgAN and HSN
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Aims of the study 
The aims of the study were as follows:
• to evaluate the clinical and histopathological features of IgAN and 
HSN in the renal biopsy material of a university clinic with mild indi-
cations for performing renal biopsy (I,II)
• to determine predictors of the outcome of IgAN in adults, and es-
pecially in patients with normal renal function at the time of diag-
nosis (I)
• to determine factors which are independently associated with pro-
gression of renal disease in initially mild IgAN, and to create a model 
for estimating the risk of progression in individual patients with nor-
mal renal function at the time of diagnosing IgAN (I)
• to identify factors affecting the outcome of HSN in adults (III)
• to compare clinical and laboratory features and outcomes of IgAN in 
adults between four medical centres on three continents (II) 
• to study the urinary excretions of cytokines IL-1β and IL-1ra in adults 
with IgAN and HSN and the correlate these levels to the degree of 
histopathological damage and clinical factors (IV)
Aims of the study
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Study design and subjects 
The subjects in Studies I–IV are characterized in Table 1.
The Finnish patients in Studies I–IV were obtained from the renal 
biopsy material of the Division of Nephrology, Helsinki University Central 
Hospital, during a 16-year period in 1980–1995. Patients diagnosed in 
1996–1998 were included in Study IV. 
Table 1 Subjects in Studies I–IV. 
   Number of patients Mean age
Study Subjects (male / female) (yrs)
I IgAN patients, diagnosed in 1980–1995
  follow-up > 3 years, or ESRF 259 (165 / 94) 36.6
II IgAN patients * 711 (469 / 242)
  from Helsinki, Finland  204 (128 / 76) 34.9
  from Glasgow, UK 112 (24 / 88) 37.3
  from Sydney, Australia 121 (73 / 48) 33.9
  from Toronto, Canada 274 (176 / 98) 37.0 
III HSN patients, diagnosed in 1980–1995
  follow-up > 1 years, or ESRF 38 (18 / 20) 42.0
IV IgAN patients, 241 (151 / 90) 42.9
  diagnosed in 1980–1995, 
  24 h-urine collected at follow-up visit 194 (121 / 73) 44.3
  diagnosed in 1996–1998, 
  24 h-urine collected 
  at the time of renal biopsy 47 (30 / 17) 37.2
 HSN patients, 26 (13 / 13) 46.8
  diagnosed in 1980–1995, 
  24 h-urine collected at study 
  follow-up visit 17 (8 / 9) 49.9
  diagnosed in 1996–1998, 
  24 h-urine collected 
  at the time of renal biopsy 9 (5 / 4) 38.2
 Healthy subjects 33 (21 / 12) 37.0
* Patients’ inclusion as described in detail in Study II.
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A total of 313 patients were diagnosed as having IgAN in 1980–1995, 
and 47 patients in 1996–1998. 42 patients were diagnosed as having HSN 
in 1980–1995, and nine in 1996–1998.
204 patients from Helsinki, Finland, 112 patients from Glasgow, United 
Kingdom, 121 patients from Sydney, Australia, and 274 patients from To-
ronto, Canada, participated in Study II. The data from Helsinki were col-
lected retrospectively and updated prospectively, the data from Glasgow 
were extracted from electronic databases in two University clinics retro-
spectively. The data from Sydney were collected retrospectively from sev-
eral medical centres and the data from Toronto were collected pro spect-
ively from several medical centres contributing to the Toronto Metro 
Glomerulonephritis Registry. Thirty-three healthy volunteers served as 
control subjects in Study IV. 
The study protocol was approved by the local ethics committee. 
Study I 
Subjects
259 of the 313 primary IgAN patients diagnosed in 1980–1995, followed 
for at least 3 years, or who reached ESRF within the fi rst 3 years of fol-
low-up.
Study design
Data on clinical and laboratory fi ndings at the time of renal biopsy were 
obtained from the patients’ medical records. The outcome of the patients 
was updated in 1997 and histopathological fi ndings of renal biopsies 
were evaluated. The patients were divided into two groups: (1) patients 
whose Ccr was < 85 ml / min, and (2) patients whose Ccr was ≥ 85 ml / min 
at the time of diagnosis. Both groups were further divided into two sub-
groups: non-progressors (subgroups 1A and 2A) and progressors, (sub-
groups 1B and 2B). The patients were classifi ed as progressors if there 
was at least 20% decrease in Ccr by the end of follow-up. If the patient 
by the end of follow-up still had normal Ccr (≥ 85 ml / min) he / she was 
considered as a non-progressor.
Univariate analyses were used to fi nd signifi cant differences between 
progressors and non-progressors in both groups. Logistic regression ana-
lysis was used to determine factors independently associated with pro-
gression in patients with normal renal function at diagnosis. 
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Study II
Subjects
204 biopsy-proven IgAN patients from Helsinki, Finland, 112 patients 
from Glasgow, UK, 121 patients from Sydney, Australia, and 274 patients 
from Toronto, Canada. 
Study design
Data on clinical and laboratory fi ndings were obtained from the data-
bases of each medical centre. Two outcomes were analyzed. The fi rst was 
renal survival as assessed by the time to development of ESRF censored 
for those lost to follow-up and death due to causes other than ESRF. The 
second was the slope of creatinine clearance against the duration of fol-
low-up. A separate post hoc analysis of patients presenting after renal im-
pairment had developed was also performed to examine factors affecting 
progression after renal impairment was established (Ccr < 75 ml / min).
Study III
Subjects
38 of the 42 HSN patients diagnosed in 1980–1995, followed for at least 
one year or who reached ESRF within the fi rst year of follow-up.
Study design
Data on clinical and laboratory fi ndings at the time of renal biopsy were 
obtained from the patients’ medical records. The outcome of the patients 
was updated in 1997 and histopathological fi ndings of renal biopsies 
were evaluated. The patients were divided into two groups on the basis 
of renal function at the last follow-up visit: non-progressors (Group 1) 
and progressors (Group 2). Patients were assigned to Group 2 if there was 
at least 20% decrease in Ccr by the end of the follow-up period. Associ-
ations between progression and clinical, laboratory or histo pathological 
variables were analyzed. A separate analysis of predictors of outcome 
was performed for a subgroup of patients whose Ccr was ≥ 85 ml / min at 
the time of diagnosis.
Study IV
Subjects
The study involved 241 patients with biopsy-proven IgAN and 26 with 
HSN. Twenty-four-hour urine samples were collected at the time of renal 
biopsy from 47 IgAN patients and from nine HSN patients, diagnosed 
Study IV
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in 1996–1998. Twenty-four-hour urine samples were collected from 211 
patients (194 with IgAN and 17 with HSN) on average 9.4 years after 
diag nostic renal biopsy in 1997. Thirty-three healthy individuals served 
as controls.
Study design
Amounts of IL-1β and IL-1ra excreted in the 24-hour urine samples were 
measured. The 2.5th percentile of the levels for the healthy control indi-
viduals was defi ned as the lower limit of normal, and the 97.5th percen-
tile was defi ned as the upper limit of normal. Histopathological fi ndings 
of renal biopsies of patients with concominant 24-hour urine samples 
and renal biopsy samples were evaluated. 
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Methods
Renal biopsy indications 
Studies I and III comprised patients who had been biopsied in 1980–1995. 
In Study IV patients diagnosed in 1996–1998 were included. Indication 
for renal biopsy at the Division of Nephrology, Helsinki University Hos-
pital, was the occurrence of persistent urinary abnormalities: microscopic 
and / or macroscopic hematuria, and / or proteinuria more than 0.2 g / 24 h, 
and / or declining renal function.
In Study II renal biopsies were performed on the patients from Glas-
gow, Sydney and Toronto. The renal biopsy indications differed between 
the four medical centres. In Helsinki, isolated microscopic hematuria was 
an indication for renal biopsy even when renal function was normal. 
In Sydney these patients were biopsied in case of need of diagnosis for 
insurance purposes. In Glasgow and Toronto, proteinuria > 1 g / 24 h or 
renal insuffi ciency were required.
Assessment of diagnosis of IgAN and HSN
Diagnostic criteria for IgAN are described in Study I and for HSN in Study III.
Assessment of medical history 
and laboratory examination
Data collection
A careful medical history was collected from medical records. Episodes of 
macroscopic hematuria before diagnosis and / or acute infection immedi-
ately prior to diagnosis were recorded. Extrarenal symptoms of HSN were 
recorded, as well as the medications used. Hypertension was considered 
present if anti-hypertensive agents were used, or supine sys tolic blood 
pressure was > 140 mmHg and / or diastolic blood pressure was > 90 mmHg, 
measured by auscultation using standardized Hg-sphygmo manometers 
in hospital.
Laboratory tests, taken at the time of renal biopsy, included quantita-
tive microscopy of a centrifuged morning urine specimen, 24-hour protein 
excretion in the urine, creatinine clearance, and serum creatinine, choles-
terol, urate and albumin levels. All laboratory data were obtained using 
standard procedures of the Helsinki University Hospital Laboratory.
Assessment of medical history and laboratory examination
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Hospital records were supplementied with a questionnaire, sent to all 
patients diagnosed in 1980–1995 in Helsinki. Follow-up information re-
garding renal function, urinary fi ndings, blood pressure values and medi-
cation was recorded from visits to outpatient clinics.
IgAN patients 
Between January 1980 and December 1995 (16 years) 313 patients (206 
males, 107 females) were diagnosed with primary IgAN, representing 
21.5% of all diagnostic renal biopsies.
By the end of 1997, only 50 patients (without ESRF) were followed at 
our outpatient clinic. The number of deaths (23 patients, 6 with ESRF), 
causes of death were confi rmed from death certifi cates kept by Stat-
istics Finland. The number of patients with ESRF (21) was ascertained. A 
question naire was sent to 219 patients who had been referred elsewhere. 
The patients were invited to a follow-up visit which included blood and 
urine samples, a physical examination and an interview. Blood samples 
were analyzed using standard procedures of the Helsinki University Hos-
pital Laboratory. The 24 h urinary samples were collected and stored at 
−20°C until analysis for Study IV. Furthermore, clinical data on blood pres-
sure, medication, urinalysis fi ndings and serum creatinine values, were 
received from associated medical centres. The data on 24 patients (7.7%) 
were not available when patient status was updated in 1997. 
Data from Sydney were collected retrospectively from several med ical 
centers, the data from Glasgow from two centres and the data from To-
ronto were collected from several medical centres contributing to the 
Toronto Metro Glomerulonephritis Registry. 
HSN patients 
The data collection of HSN patients for Study III was conducted similarly 
to that of IgAN patients in Study I. Between January 1980 and December 
1995, 42 patients (20 males, 22 females) were diagnosed with HSN, repre-
senting 3.3% of all diagnostic renal biopsies. 
By the end of 1997, only 5 of the original 42 patients attended our 
outpatient clinic. Three of these had progressed to ESRF. One had died of 
non-renal causes. Data relating to fi ve patients were not available when 
patient status was updated in 1997. 
Assessment of renal function
Estimated creatinine clearance (Ccr) was calculated by the Cockcroft–
Gault formula (Cockcroft and Gault 1976). In Study IV Ccr was measured 
either by the classic 24-hour urine creatinine excretion and simultaneous 
serum creatinine, or calculated by the formula of Cockcroft and Gault if 
only serum creatinine was available. In Studies I, III, and IV renal function 
was regarded as normal, if Ccr was ≥ 85 ml / min, and impaired if Ccr was 
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< 85 ml / min. In the international comparison Study (II) renal function was 
regarded impaired if Ccr was < 75 ml / min. 
Assessment of progression of renal disease
In Studies I and III the patients were classifi ed as progressors if there 
was at least 20% impairment of renal function by the end of follow-
up. However, if by the end of follow-up the patient still had normal Ccr 
(≥ 85 ml / min) he / she was considered as a non-progressor. Renal survival 
and slope of Ccr were used as determinants of outcome, and are defi ned 
in Study II. The patient was defi ned as having ESRF when renal replace-
ment therapy (dialysis) was started (I, III, IV) or when Ccr was < 15 ml / 
min (II).
Assays 
Urinary IL-1ra levels were determined by an enzyme immunoassay (Teppo 
et al. 1998) and IL-1β levels by radioimmunoassay (Maury and Teppo 
1987). The detection limit of the assay method for IL-1ra was 20 ng / l and 
for IL-1β 5 ng / l. Concentrations below the detection limits were recorded 
as equal to the detection limit. IL-1ra and IL-1β excretion levels were re-
lated to concomitant urinary creatinine (Ucr) excretion levels. IL-1ra / IL-1β 
ratios were calculated. 
Excretion levels were determined for the healthy control individuals. 
The 2.5th percentile of the levels for these control individuals was de-
fi ned as the lower limit of normal, and the 97.5th percentile was defi ned 
as the upper limit of normal (Altman 1991).
Histopathological evaluation of renal biopsies 
The evaluation and grading of renal biopsies are described in detail in 
Studies I, III and IV.
Statistical analyses
Statistical calculations were performed using the Mann–Whitney U-test, 
the paired t-test and Pearson’s Chi-squared test, Spearman’s correlation 
test, linear regression, logistic regression and the Hosmer–Lemeshow test 
(I,III, IV). Renal survival was calculated using the Kaplan–Meier method 
(II, III). 95% confi dence intervals were calculated using SAS 6.12 (I). In 
Study II ANOVA (analysis of variance), Cox proportional hazards model, 
the log rank test, linear regression and Kruskal–Wallis H test were used. 
P-values < 0.05 were considered statistically signifi cant in all cases. 
Statistical analyses
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Results 
IgAN (I, II)
Clinical features at time of diagnosis (I)
Ninety-eight out of the 259 patients (38%) had Ccr values < 85 ml / min at 
the time of renal biopsy. 161 (62%) had normal renal function (Ccr ≥ 85 ml / 
min). Isolated microscopic hematuria was the only clinical fi nding in 32 
patients (12%). Proteinuria was in the nephrotic range (> 3.5 g / 24 h) in 
28 subjects (11%). Seventy patients (27%) had experienced episode(s) of 
macroscopic hematuria and 85 (33%) were hypertensive at the time of 
diagnosis. 
The clinical and laboratory fi ndings at the time of renal biopsy are 
presented in Table 2.
Histopathology (I)
Four per cent of the patients had normal renal histology on light micro-
scopy. Grade-0 histopathological fi ndings were common: in 47% of the 
patients in relation to mesangial cell proliferation, in 16% in relation to 
matrix increase, in 23% in relation to tubular atrophy, in 32% in relation 
to interstitial fi brosis, in 44% in relation to interstitial cell infi ltration, 
and in 74% in relation to arteriolosclerosis. Fifteen percents of the pa-
tients had glomerular crescents and / or necrosis. 
Outcome (I)
Totally 116 patients (45%) exhibited only isolated microscopic hematuria 
or normal urinary fi ndings and 168 patients (65%) were hypertensive 
at the time of fi nal follow-up. Hypertension was more common in the 
progressors than in patients with stable renal function: 88% of the pro-
gressors were hypertensive vs 55% of the non-progressors. 
In the mean follow-up time of 9.1 years, the renal disease had pro-
gressed in 80 patients (31%), and ESRF was reached in 25 patients (10%). 
Eight of the 32 patients with isolated microscopic hematuria at the time 
of diagnosis showed progression and 13 had hypertension. Four patients 
with initially normal renal function had progressed to ESRF. 
Factors associated with progression in IgAN (I)
Findings in univariate analyses
The factors found to be statistically signifi cantly associated with progres-
sion in patients with decreased renal function on diagnosis (Ccr < 85 ml / 
43
min) were: male sex, no history of episodes of macroscopic hematuria, 
presence of hypertension, decreased Ccr, higher amounts of proteinuria, 
serum cholesterol and serum urate. The outcomes were better in patients 
on antihypertensive therapy at the time of biopsy than in patients whose 
hypertension had not been treated before diagnosis. The histo patho-
logical fi ndings that differed signifi cantly between the non-progressors 
and the progressors were: mesangial proliferation, mesangial matrix in-
crease, interstitial fi brosis, tubular atrophy and arteriolosclerosis. High 
Table 2 Clinical and laboratory fi ndings on biopsy.
 Patients with decreased renal func- Patients with normal renal func- 
 tion (Ccr < 85 ml / min) at diagnosis tion (Ccr ≥ 85 ml / min) at diagnosis
 Non-   Non- 
 progressors Progressors P-value  Progressors Progressors P-value 
Number 
 of patients 59 39  120 41 
Follow-up 
 (years) 8.2 (3.4) 6.1 (4.2) < 0.05 10.1 (4.3) 10.6 (4.4)  NS
Sex (M / F, % 
 of patients) 36 / 64 59 / 41 < 0.05 74 / 26 78 / 22.  NS
Age (years) 43.1 (1.7) 47.1 (14.1)  NS 30.9 (10.8) 34.1 (10.6)  NS
History of 
 macroscopic 
 hematuria 
 (% of patients) 39 5 < 0.001 29 24  NS
Hypertensive 
 patients
 (% of patients) 28.8 71.8 < 0.001 18.3 43.9 < 0.01
Antihypertensive 
 medication on 
 biopsy (% of 
 hypertensive 
 patients) 64.7 78.6 < 0.01 86.4 55.6  NS
Ccr (ml / min) 66.3 (15.1) 53.1 (19.1) < 0.01 110.0 (16.1) 102.7 (12.9) < 0.05
dU-prot (g / 24 h) 0.8 (1.6) 3.2 (2.8) < 0.001 0.9 (1.7) 2.1 (2.3) < 0.01
Urinary erythro-
 cytes (per high 
 power fi eld) 24.8 (45.3) 34.3 (54.6)  NS 26.9 (50.2) 53.2 (77.1) < 0.05
s-albumin (g / l) 35.5 (3.8) 33.4 (5.0)  NS 39.0 (4.8) 35.3 (3.9) < 0.01
s-cholesterol 
 (mmol / l) 5.8 (1.3) 6.7 (1.9) < 0.05 5.2 (1.1) 6.3 (1.6) < 0.001
s-urate (µmol / l) 313.2 (126.6) 402.0 (120.8) < 0.01 320.3 (72.4) 348.3 (92.4)  NS
Note: Values expressed as means (SD) or % of patients.
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glomerular, tubulointerstitial and total histopathological scores were 
also associated with progression. In the 35 patients with Ccr < 60 ml / min 
at the time of renal biopsy, hypertension, level of proteinuria, male sex, 
no history of episodes of macroscopic hematuria and level of serum urate 
associated with further progression of the disease.
In patients with normal renal function on diagnosis (Ccr ≥ 85 ml / min) 
hypertension, number of urinary erythrocytes, and level of Ccr, protein-
uria, serum albumin and cholesterol were found to differ statistically 
signifi cantly between the non-progressors and the progressors. The histo-
patho logical factors associated with progression were the same in both 
main groups, except for tubular atrophy, which was signifi cantly associ-
ated with outcome in patients with decreased renal function at diagnosis 
(Ccr < 85 ml / min). None of the histopathological fi ndings were associated 
with further progression in the group of patients with Ccr < 60 ml / min at 
the time of diagnosing IgAN. 
Findings in multivariate analysis
In the multivariate analysis of factors related to progression in patients 
with normal renal function on diagnosis, the number of urinary erythro-
cytes, presence of hypertension, arteriolosclerosis, and a glomerular score 
of 2 or more were found to serve as independent factors of outcome 
(Table 3). 
The probabilities of progression in relation to various combinations of 
these four variables were calculated and are shown in Table 4.
A tricontinental view of IgAN (II)
Totally 711 adult patients with biopsy-proven IgAN from the four medical 
centres were included in the study; 204 from Helsinki, Finland, 112 from 
Table 3 Results of logistic regression analysis of patients with normal renal function 
at diagnosis (Ccr ≥ 85 ml / min) with progression as a dependent variable. Complete 
data available on 146 / 161 patients.
 Regression Standard  Odds 95% CI 95% CI
Variable coeffi cient error P-value ratio lower upper
Urinary erythrocytes
 (per high power fi eld) 0.0085 0.0034 0.0137 1.0085 1.0017 1.0153
Hypertension 1.0983 0.4897 0.0249 2.9990 1.1485 7.8316
Arteriolosclerosis 1.0294 0.5104 0.0437 2.7993 1.0294 7.6124
Glomerular score 0.9796 0.4463 0.0282 2.6634 1.1106 6.3871
Constant −2.4759 0.4139 0   
Hosmer-Lemeshow 
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Glasgow, UK, 121 from Sydney, Australia, and 274 from Toronto, Canada. 
The baseline clinical data are shown in Table 5.
There was signifi cant variability in renal survival between the four 
centres with 10-year actuarial survival of 95.7%, 87.0%, 63.9% and 
61.6% in Helsinki, Sydney, Glasgow and Toronto, respectively. In the 
univariate analysis, gender had no signifi cant impact on renal survival, 
whereas higher age, lower Ccr, greater amount of proteinuria and in-
creased mean arterial pressure (MAP) were all associated with shortened 
renal survival.
Signifi cant independent predictors of shorter renal survival were: 
younger age (hazard ratio (HR) 0.98 per year, p = 0.05), greater amount 
of proteinuria (HR 1.13 per g / 24 h, p < 0.0001) and lower Ccr (HR 0.96 
per ml / min, p < 0.0001). In addition, the patients from Helsinki (HR 0.30, 
p = 0.002) and Sydney (HR 0.34, p = 0.003), but not from Glasgow, had 
signifi cantly longer renal survival than the patients from Toronto, in-
dependent of age, amount of proteinuria, level of Ccr, gender, or MAP. 
When each variable with a signifi cant independent effect was analysed 
over the range of values within the cohort, the level of Ccr had the great-
est impact on renal survival, followed by the amount of proteinuria, 
Helsinki, Sydney, and age (Table 6). 
Table 5 Clinical characteristics of patients with biopsy-proven IgA nephropathy at 
presentation.
 Glasgow  Helsinki Sydney Toronto
 (n = 112) (n = 204) (n = 121) (n = 274)
Median year of presentation 
 (range)  1989 (77–95) 1987 (80–95) 1985 (59–93) 1984 (63–97)
Median follow-up (months) 86 123 73 53
Mean (SD) age (years) 37.3 (14.3) 34.9 (12.5) 33.9 (12.1) 37.0 (12.3)
Sex (M / F, % of patients) 21 / 79 63 / 37 60 / 40 64 / 36
Median serum creatinine 
 (µmol / l) 118 90 110 115
Mean (SD) Ccr (ml / min) 79.1 (40.7) 98.7 (28.4) 82.6 (33.5) 74.2 (30.9)
Proportion of patients 
 presenting with 
 Ccr < 75 ml / min (%) 46.4  16.7  42.1  48.2
Median urine protein 
 (dU-prot) excretion (g / 24 h) 1.72 0.64 1.28 1.75
Proportion of patients with 
 dU-prot < 0.5 g / day (%) 22.9 46.4 26.2 5.7
Mean (SD) of mean arterial 
 blood pressure (mmHg) 105 (14.4) 94.0 (12.9) 103 (13.9) 105 (17.0)
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There was signifi cant geographical variability in the rate of lower ed 
renal function. Median slope Ccr was −1.24 ml / min / year in Helsinki, 
−2.95 ml / min / year in Sydney, −3.46 ml / min / year in Glasgow, and −3.99 ml / 
min / year in Toronto. In the univariate analysis, high Ccr, low amount 
of proteinuria and low MAP were all signifi cantly associated with a less 
nega tive slope of Ccr. In the multivariate analysis, older age (standard-
ised co-effi cient [β] 0.11; p = 0.02), higher Ccr (β 0.11; p = 0.03), and lower 
amount of proteinuria (β –0.33; p < 0.0001) were associated with a less 
negative slope. In addition, the subjects from Helsinki (β 0.12; p = 0.03), 
but not from Sydney (β 0.08; p = 0.092) or Glasgow (β 0.049; p = 0.3), had 
a signifi cantly slower rate of deterioration independent of the other clin-
ical parameters at presentation, when Toronto was the reference center. 
The amount of proteinuria had the greatest impact on the slope of Ccr. 
When the 269 patients presenting with Ccr < 75 ml / min were analysed 
separately, higher age (β 0.22; p = 0.01), higher Ccr (β 0.22; p = 0.001) 
and lower level of proteinuria (β −0.34; p < 0.001) were associated with 
a less negative slope of Ccr, but there was no independent center effect 
(Table 7). 
Analysis of the 413 patients who presented with Ccr ≥ 75 m l / min re-
vealed a higher level of dU-prot (β −0.29; p < 0.001) as an independent 
predictor of the subsequent slope of Ccr, but not age or Ccr. In addition, 
the patients from Helsinki (β 0.23; p = 0.002) had a signifi cantly less nega-
tive slope of Ccr, independent of the clinical parameters (Table 8).
Table 6 Cox proportional hazards univariate and multivariate analysis of clinical 
features at presentation, and subsequent renal survival. Hazard ratio > 1.0 implies 
shorter renal survival.
 Univariate analysis Multivariate analysis
 Hazard  Hazard
 ratio (HR) P-value ratio (HR) P-value
Age (per year) 1.02 0.001 0.98 0.05
Male gender 1.17 0.39 1.03 0.91
Ccr (per ml / min) 0.96 < 0.001 0.96 < 0.001
dU-prot (per g / 24 h) 1.2 < 0.001 1.13 < 0.001
MAP (per mmHg) 1.03 < 0.001 1.003 0.64
Glasgow 2.0 0.002 1.2 * 0.38
Helsinki 0.20 < 0.001 0.30 * 0.002
Sydney 0.65 0.10 0.34 * 0.003
Toronto 2.37 < 0.001 _* _
* Reference center Toronto.
IgAN (I, II)
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Table 7 Linear regression univariate and multivariate analysis of clinical features at 
presentation and subsequent slope of Ccr. Standardised co-effi cient (β) < 0.0 implies 
that the independent variable caused a more rapid deterioration in renal function 
and vice versa. 
 Univariate analysis Multivariate analysis
 Standardised  Standardised
  co-effi cient (β)  P-value  co-effi cient (β)  P-value
Age (per year)  0.032  0.4  0.11  0.02
Male gender −0.07  0.06 −0.034  0.44
Ccr (per ml / min)  0.18 < 0.001  0.11  0.03
dU-prot (per g / 24 h) −0.39 < 0.001 −0.33 < 0.001
MAP (per mmHg) −0.21 < 0.001 −0.085  0.09
Glasgow −0.07  0.06  0.049 *  0.3
Helsinki  0.21 < 0.001  0.12 *  0.03
Sydney  0.017  0.65  0.08 *  0.092
Toronto −0.16 < 0.001  _ *  _
* Reference center Toronto.
Table 8 Multiple linear regression analysis of clinical features at presentation and 
subsequent slope of Ccr for patients presenting with Ccr < 75 ml / min and for patients 
presenting with Ccr ≥ 75 ml / min. Standardized co-effi cient (β) < 0.0 implies that the 
independent variable caused a more rapid deterioration in renal function.
 CrCl < 75 ml / min (n = 269) CrCl ≥ 75 ml / min (n = 413)
 Standardised  Standardised
 co-effi cient (β) P-value co-effi cient (β) P-value
Age (per year) 0.22 0.01 0.046 0.45
Male gender  0.027 0.68 0.063 0.28
Ccr (per ml / min) 0.22 0.001 0.003 0.96
dU-prot (per g / 24 h) −0.34 < 0.001 −0.29 < 0.001
MAP (per mmHg) −0.12 0.08 0.002 0.97
Glasgow  0.026 0.7 0.12 * 0.09
Helsinki −0.007 0.92 0.23 * 0.002
Sydney  0.12 0.059 0.02 * 0.74
* Reference center Toronto.
49
HSN (III)
Clinical features at time of diagnosis
Thirty-eight patients with HSN were included in Study III. Purpura pre-
ceded urinary abnormalities in 31 patients and in seven patients it fol-
lowed urinary abnormalities. The patients in whom urinary fi ndings pre-
ceded purpura were older than those in whom purpura was the fi rst 
symptom of the disease (mean age 53.9 years versus 39.3 years p < 0.05). 
Eleven patients had suffered an acute infection prior to renal biopsy. Nine 
patients had experienced bowel pain, eight patients arthritis / arthralgia. 
Eleven of the patients had had isolated microscopic hematuria as an in-
dication for renal biopsy. In 10 patients the proteinuria values lay in the 
nephrotic range (> 3.5 g / 24 h). Four patients had experienced episodes 
of macroscopic hematuria before renal biopsy. At diagnosis, 25 patients 
(66%) had Ccr ≥ 85 ml / min, and 16 patients (42%) were hypertensive. 
Clinical fi ndings at the time of renal biopsy are presented in Table 9.
Table 9 Clinical and laboratory fi ndings on biopsy. Values expressed as means (± SEM) 
or percentages of patients.
Variable Non-progressors Progressors  P-value 
Number of patients 30 8 
Follow-up (years) 6.0 (± 0.8) 6.2 (± 1.9) NS
Sex (M / F, % of patients) 43 / 57 63 / 37 NS
Age (years) 42.2 (± 3.1) 41.4 (± 5.2) NS
History of macroscopic 
 hematuria (% of patients) 10 13 NS
Prediagnostic acute 
 infection (% of patients) 27 38 NS
Existence of hypertension 
 (% of patients) 37 63 NS
Ccr (ml / min) 94.3 (± 7.2) 72.3 (± 9.4) NS
dU-prot (g / 24 h) 2.1 (± 0.5) 6.0 (± 2.8) NS
dU-prot > 1.0 g / 24 h 
 (% of patients) 47 88 < 0.05
Urinary erythrocytes 
 (per high power fi eld) 23.3 (± 6.4) 12.6 (± 4.5) NS
Serum albumin (g / l) 33.9 (± 5.9) 25.2 (± 4.0) NS
Serum cholesterol 
 (mmol / l) 5.9 (± 0.4) 5.2 (± 0.2) NS
Serum urate (µmol / l) 331.3 (± 41.5) 379.8 (± 43.5) NS
HSN (III)
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Histopathology
One patient had normal renal histology. Grade-0 changes were seen in 
8% of the patients in relation to mesangial cell proliferation, in 24% of 
the patients in relation to matrix increase, in 16% of the patients in re-
lation to tubular atrophy, in 18% of the patients in relation to interstitial 
fi brosis, in 26% of the patients in relation to interstitial cell infi ltration, 
and in 79% of the patients in relation to arteriolosclerosis. 18% (6 / 33) 
presented with glomerular necrosis and / or crescents. 
Outcomes
There was progression of HSN during follow-up in eight patients (21%), 
and in four cases (11%) the disease progressed to ESRF. The Ccr level of 4 
progressors had initially been ≥ 85 ml / min. 
Twenty-one patients (55%) exhibited only isolated microscopic hema-
turia or normal urinary fi ndings by the end of follow-up. 27 patients 
(71%) were hypertensive. 19 out of 30 non-progressors (63%) and all 8 
progressors were hypertensive at the time of fi nal follow-up.
Factors associated with progression 
There was a statistically signifi cant difference between progressors and 
non-progressors only in the number of patients whose proteinuria ex-
ceeded 1.0 g / 24 h on diagnosis (46.7% versus 87.5%, p < 0.05) (Table 9). 
In patients whose renal function was normal (Ccr ≥ 85 ml / min, 25 pa-
tients) hypertension was more common among the progressors (n = 4) 
than the non-progressors (n = 21) at the time of biopsy (75% versus 19%, 
p < 0.05). The Ccr values were also signifi cantly lower in the former group 
(92.3 ml / min versus 118.8 ml / min, p < 0.05), as were the serum albumin 
levels (19.3 g / l versus 34.7 g / l p < 0.05).
Urinary excretion of IL-1β and IL-1ra in IgAN and HSN (IV)
There were no statistically signifi cant differences in any clinical or histo-
pathological feature between IgAN and HSN patients, except in the his-
tory of extrarenal manifestation.
Urinary excretion of IL-1ra in healthy subjects was 21.7 (1.3–271.1) ng / 
mmol / Ucr, in IgAN patients 9.0 (0.5–1029.4) ng / mmol / Ucr and in HSN 
patients 46.3 (2.7–647.1) ng / mmol / Ucr. Excretion of IL-1β was 1.1 (0.3–
6.4) ng / mmol / Ucr in healthy controls, 1.0 (0.2–27.5) ng / mmol / Ucr in IgAN 
patients and 1.0 (0.4–5.1) ng / mmol / Ucr in HSN patients. IL-1ra / IL-1β ratio 
was 30.0 (2.5–244.0) in controls, 8.0 (0.8–700.0) in IgAN patients and 31.3 
(3.0–910.0) in HSN patients. Patients with IgAN excreted IL-1ra signifi -
cantly less than did normal subjects (p < 0.05) and less than HSN patients 
(p < 0.01), but excretion of IL-1β did not differ statistically between the 
groups (Figure 4).
Figure 4 Urinary excre-
tion levels of IL-1ra, IL-1β 
and IL-1ra/IL-1β ratio in 
IgAN and HSN patients 
and in healthy controls. 
The boxes indicate 
the lower and upper 
quartiles. The central 
lines (and numbers) in 
the boxes indicate the 
median values.
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Urinary IL-1ra or IL-1β levels did not correlate with the degree of 
protein uria, number of urinary erythrocytes, follow-up time from diag-
nostic renal biopsy or age of the patients. None of the histopathological 
variables correlated with IL-1ra or IL-1β excretion either. The excretions 
of IL-1ra and IL-1β and the levels of IL-1ra / IL-1β were signifi cantly higher 
in female patients compared to male patients in both patient groups, 
and also in healthy controls. 
Twenty patients (16 IgAN and 4 HSN patients) had an IL-1ra / IL-1β ratio 
above the reference limits (Table 10). Patients with a high IL-1ra / IL-1β 
ratio had milder histopathological changes in renal biopsy when com-
pared with patients with a low / normal IL-1ra / IL-1β ratio. There was no 
statistically signifi cant difference between the patients with a high and 
normal / low IL-1ra / IL-1β ratio in relation to Ccr, proteinuria, microscopic 
hematuria or follow-up time from renal biopsy. 
Table 10 Patients whose urinary excretion levels of IL-1ra, IL-1β and IL-1ra / IL-1β 
ratios were outside the normal range as defi ned below. Values are expressed as 
numbers of patients (% of patients).
  IgAN patients HSN patients P-value
IL-1ra, ng / mmol Ucr Above normal range  12 (6%) 6 (23%) < 0.01
 Below normal range 46 (18%) 1 (4%) < 0.01
IL-1β, ng / mmol Ucr Above normal range  13 (5%) 0 
 Below normal range 16 (7%) 0 
IL-1ra / IL-1β Above normal range  16 (7%) 4 (15%) < 0.01
 Below normal range 66 (27%) 1 (4%) < 0.01
Note: Excretion levels were determined for healthy control individuals. The 2.5th percentile of 
the levels for these healthy control individuals was defi ned as the lower limit for normal, the 
97.5th percentile as the upper limit for normal. For IL-1ra the normal range, as defi ned above, 
was 1.3–132.6 ng / mmol Ucr in men and 18.5–271.1 ng / mmol Ucr in women. For IL-1β the 
normal range was 0.3–5.5 ng / mmol Ucr in men and 0.6–6.4 ng / mmol Ucr in women. For IL-1ra / 
IL1β ratio the normal range was 2.5–244.0 ng / mmol Ucr in men and 10.0–164.3 ng / mmol Ucr 
in women.
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Discussion
Subjects and Methods
Selection of patients
The patients in Studies I and III had been diagnosed by renal biopsy at 
the Division of Nephrology, Helsinki University Hospital, during a 16-year 
period from 1980 to 1995, and a two-year period from 1996–1998 (IV). 
All patients with IgAN (I, II, IV) or HSN (III) were included. Clinical, histo-
pathological and laboratory data at the time of renal biopsy and follow-
up visits were retrospectively recorded. Clinical and laboratory data were 
updated in 1997. The participation rate in the prospective part was high: 
92% for IgAN patients and 87% for HSN patients. In 1980–1995, indica-
tion for renal biopsy was the occurrence of persistent urinary abnormali-
ties: microscopic and / or macroscopic hematuria and / or proteinuria more 
than 0.2 g / 24 h and / or declining renal function. Thus, isolated micro-
scopic hematuria with normal renal function was a suffi cient indication 
for renal biopsy. A large proportion of the patients were referred from 
the Finnish defence force, and employment and driving licence screening 
programmes which partly explains why many of the patients had clinic-
ally mild disease.
In Study I, a follow-up period of at least three years was required, 
and in Study III a follow-up of at least of one year. A minimum follow-
up of one (D’Amico et al. 1985, Szeto et al. 2001) to three years has 
been widely used in studies investigating factors affecting outcome in 
slowly progressing diseases such as IgAN and HSN. If the minimum fol-
low-up time is short, the study would underestimate the number of pa-
tients with a progressive disease. A shorter follow-up time requirement 
for patients with HSN was set because the number of HSN patients was 
small. Adult patients with biopsy-proven IgAN from the four countries 
were included in Study II. The patients from Glasgow included patients 
from two university medical centers in 1977–1995, and the data were 
collected retrospectively. The patients from Sydney were from the years 
1959–1993 and collected retrospectively from several Australian medical 
centers. The patients from Toronto presented in 1963–1997 and had been 
collected from several Canadian medical centers. The patients from Hel-
sinki were the ones investigated in Study I. The patients were included in 
Study II using strict criteria, depending on the calculated slope of Ccr. If 
the follow-up was > 2 years and the slope of Ccr was less negative than 
−1.0 ml / min / year (stable renal function), two measurements of Ccr dur-
ing the follow-up were considered to be suffi cient for inclusion. If the 
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slope was more negative, a minimum of three measurements during the 
follow-up were required. The biopsy indications in the four countries dif-
fered greatly. The patients from Helsinki were referred to renal biopsy 
with mild clinical fi ndings discovered mainly in screening programs, as de-
scribed. In 1997 when the patient data was updated, most of the Finnish 
patients were followed in primary health care instead of our outpatient 
clinic. The repeated Ccr values during follow-up were, thus, not available 
in all cases. In Sydney the patients with isolated microscopic hematuria 
were biopsied, but only occasionally, for instance, if needed for insur-
ance. The patients in Toronto and Glasgow, in contrast, were unlikely to 
undergo biopsy, unless they had heavy proteinuria or renal failure. Due 
to the methodology used to include patients, and the proportion of pa-
tients having mild disease at renal biopsy, more progressors from Helsinki 
may have been excluded from the study. However, the patients from Syd-
ney were collected using the same criteria (Ibels and Gyory 1994) as the 
patients from Helsinki. Therefore, methodological aspects are not likely 
to have a major impact on the results of the study. 
Defi nition of renal function 
Most of the studies on outcome and factors affecting the prognosis of 
IgAN and HSN in adults have been retrospective. Thus, renal function has 
been determined mostly by serum creatinine, which is the most acces-
sible measurement. Serum creatinine level is nevertheless not an ideal 
marker of renal function. Creatinine is both fi ltered at the glomerulus 
and secreted by the proximal tubule and many factors can infl uence 
creatin ine levels and / or secretion (Kemperman et al. 2002b). Estimates of 
glomerular fi ltration rate (GFR) based on 24 h Ccr suffer from inaccur acies 
associ ated with timed urine collection. Classic methods for measuring 
GFR, such as inulin and CrEDTA clearance require intravenous in fusions, 
are timely and expensive, and thus not clinically feasible, especially in 
the case of retrospective studies (Kemperman et al. 2002a). On the other 
hand, serum cystatine C has in some studies been found to be a reliable 
estimate of renal function (Hoek et al. 2003). This has not yet been avail-
able for retrospective studies. If serum creatinine or 24 h Ccr are used, 
the values are age-dependent. After the age of 40, the GFR declines at 
an annual rate of approximately 0.8 ml / min / 1.73 m 2. Moreover, elderly 
patients undergo a decrease in body muscle mass and therefore produce 
less creatinine. As a result, normal levels for creatinine in young persons 
cannot be extrapolated to elderly subjects or to children (Meyer 1989).
In most studies on IgAN (Nicholls et al. 1984, D’Amico et al. 1985, Re-
kola et al. 1989, Alamartine et al. 1991, Katafuchi et al. 1994, Frimat et al. 
1997, Koyama et al. 1997, Daniel et al. 2000, Syrjanen et al. 2000b) serum 
creatinine levels have been used to defi ne renal function without factor-
ing for age. Equations based on serum creatinine but factoring for sex, 
age and body weight have been found to be a good alternative for esti-
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mating GFR (Kemperman et al. 2002a, Burkhardt et al. 2005). The most 
commonly used equations are the Cockcroft–Gault formula (Cockcroft and 
Gault 1976) and the Modifi cation of Diet in Renal Disease (MDRD) Study 
equation (Levey et al. 1999), which both have been shown to estimate 
GFR reliably (Sinton et al. 1986, Kemperman et al. 2002a, Burkhardt et al. 
2005). It should be noted that formulas predicting GFR can only be used in 
patients who are in clinically stable state. The formulas are in accurate in 
obese or edematous patients, since muscle mass would be overestimated 
(Kemperman et al. 2002a). In this thesis Ccr was calculated by the Cock-
croft–Gault formula. In Study III Ccr was calculated by the classic 24-hour 
urine creatinine excretion and simultaneous serum creatin ine in most 
cases. However, in all cases, only one method was used for each individual 
patient: Ccr measured by 24-hour urine collection only or by calculated 
creatinine clearance only. Both methods have been shown to be accurate 
(Cockcroft and Gault 1976, Kemperman et al. 2002a, Hoek et al. 2003). 
There was no universally accepted defi nition for normal renal func-
tion or chronic renal disease at the time when Studies I–IV were con-
ducted. In 2002, the National Kidney Foundation published Clinical Prac-
tice Guidelines for Chronic Kidney Disease (National Kidney 2002), in 
which chronic kidney disease was divided into fi ve stages on the basis of 
Ccr, as estimated with the Cockcroft–Gault or the MDRD formula (Levey 
et al. 1999). However, these recommendations are for clinical use, and so 
far investigators have used many different defi nitions, depending mainly 
on the patient population studied.
Renal function is still usually defi ned on the basis of serum creatinine, 
and the defi nitions most commonly used are serum creatinine < 120 or 
130 umol / l (Johnston et al. 1992, Coppo et al. 1997, Nieuwhof et al. 1998, 
Syrjanen et al. 2000a, To et al. 2000). The lower limit for Ccr in the present 
studies (I, III) was set as high as 85 ml / min, to ensure that all patients 
assigned to this group had normal renal function. This level is one of 
the highest used in the studies on IgAN and HSN. The group of patients 
having Ccr < 85 ml / min was therefore inevitably more heterogeneous. 
Therefore, the results relating to patients with chronic renal insuffi ciency 
(Ccr values of < 60 ml / min) on diagnosis were analyzed separately. The 
aim of dividing the patients into groups according to renal function at 
renal biopsy was to study whether the factors found to be associated 
with progression of IgAN were related to initial renal function or stage 
of the disease, rather than dependent on renal disease per se. In Study II, 
the patients presenting with Ccr < 75 ml / min were considered as having 
renal impairment and were analyzed separately in an attempt to over-
come potential biases in the patient selection from the four countries. 
Defi nition of progression 
In a slowly advancing disease, such as IgAN, it is diffi cult to defi ne pro-
gression. Most studies on IgAN and HSN have used dichotomous end-
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points. ESRF, which is most commonly used, is easy to determine as an 
end-point. However, in a slowly progressing disease it underestimates 
the number of unfavorable events. This is particularly true in patients 
with initially normal renal function, even when follow-up times are long. 
Therefore, different defi nitions of progression have been used espe-
cially in studying populations of IgAN patients with initially normal or 
near-normal renal function. Increase in serum creatinine beyond certain 
limit, such as 124 µmol / l (D’Amico et al. 1985), 150 µmol / l (Daniel et al. 
2000) or 177 µmol / l (Gallo et al. 1988, Lai et al. 2000)) has been used to 
indicate progression. This however, may classify patients as progressors 
without notable decline of renal function. A 20 or 50% increase in serum 
creatin ine has also been used (Ibels et al. 1997, Syrjanen et al. 2000b). 
We decided to use a decline of at least 20% in Ccr to defi ne progression. 
However, many of the patients with normal renal function at the time 
of diagnostic renal biopsy had a Ccr level as high as 110 ml / min. Twenty 
percent impairment of Ccr in these patients within the follow-up time 
available would result in a Ccr level still as good as 88 ml / min, which 
was considered to be normal renal function at baseline. Therefore, if a 
patient by the end of follow-up still had normal Ccr (≥ 85 ml / min) he / she 
was considered as a non-progressor. Since the duration of IgAN cannot 
be estimated, many of the patients might have had the disease for years 
before diagnosis. It is not justifi ed to defi ne these patients as progressors, 
since their renal function remained within normal limits after a lengthy 
period of follow-up. The mean changes in Ccr per year for each subgroup 
indicate that the defi nition of progression was appropriate.
The slope of Ccr, determining changes in Ccr over time, is probably 
one of the best indicators for progression in slowly progressive renal dis-
eases. This method has been used in few studies (Miyazaki et al. 1996, 
Bartosik et al. 2001). Furthermore, the slope of Ccr is not infl uenced to 
the same extent as a dichotomous end-point, by the stage of the disease 
in which the patient is diagnosed. This makes the slope of Ccr particularly 
suitable in a multicenter study like Study II. 
IgAN 
Clinical fi ndings
Sixty-two percent of the patients (I) had normal renal function and 12% 
had isolated microscopic hematuria as the only clinical fi nding of IgAN at 
the time of renal biopsy. Considering the large number of patients with 
a clinically mild disease at the time of diagnosis, the mean age, number 
of patients having hypertension, and episodes of macroscopic hematuria 
prior to diagnosis were strikingly similar to fi ndings in other studies on 
adult IgAN (Miyazaki et al. 1996, Radford et al. 1996, Bartosik et al. 2001, 
Li et al. 2002) (Table 11). Based on a literature review, only four studies 
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in addition to the present study included adult patients only (Table 11). It 
is still controversial whether children have a better outcome than adults. 
Since only Wyatt et al. (1995) have shown similar outcome rates in chil-
dren as most adult studies, it seems reasonable to study children and 
adults in separate groups. 
Factors associated with progression 
Totally 120 of the 161 patients with normal renal function at diagnosis 
were defi ned as non-progressors (I). A large proportion of these patients 
would probably never have been biopsied in most medical centers. It 
is still not known whether there are IgAN patients who never exhibit 
progression of renal disease. However, many of the patients biopsied 
on the basis of isolated microscopic hematuria in out study progressed, 
but none of them to ESRF. On the other hand, four of the patients with 
initially normal renal function progressed to ESRF. When patients with 
different levels of renal function are studied separately, the results vary 
(Study I). In all three groups defi ned by the level of Ccr at diagnosis, only 
hypertension and degree of proteinuria were found to associate with 
further progression. These two parameters have been shown to be the 
most powerful predictors of progression in most IgAN studies (D’Amico 
2004). 
In Study I multivariate analysis was used for the fi rst time in a large 
material of adult IgAN patients with initially normal renal function to 
fi nd independent clinical and histopathological predictors of outcome. 
Four independent predictors of outcome were found, and a math emat-
ical model predicting the outcome for individual patients was created. 
Previously the number of urinary erythrocytes and the presence of ar-
Table 11 Clinical data at the time of renal biopsy in studies on adult IgAN.
 Rauta Bartosik  Radford Yagame Li et al.
 et al. (I) et al. (2001) et al. (1996) et al. (1996) (2002)
N 259 298 148 206 168
Follow-up (years) 9.1 4.8 6.3 9.2 7.4
Sex (M/F, % of patients) 63 / 37 61 / 39 72 / 28 61 / 39 39 / 61
Mean age (years) 35 – 39 30 33
Episodes of macroscopic 
 HU (% of patients) 29 – – 23 19
Hypertension 
 (% of patients) 33 – 47 – 34
Normal renal function 
 (% of patients) 62 – 41 – –
IgAN
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teriolosclerosis have not been shown to be independent predictors of 
unfavorable outcome. 
In Study II fi ve potential clinical variables were used to test their im-
pact on the outcome of IgAN in a group of 711 patients from four coun-
tries. Higher level of mean arterial pressure was found to be associated 
with severe outcome by univariate analysis, but not by multivariate ana-
lysis. Higher amount of proteinuria and lower Ccr level were statistically 
signifi cant independent factors affecting outcome. Multivariate analyses 
also showed an independent protective effect of old age on both the 
risk of developing ESRF and the slope of Ccr. Similar fi ndings were re-
ported by Radford et al. (1996). However, in most studies old age has 
been reported to be a risk factor for worse outcome. In Study II advanc-
ing age was associated with a less negative slope of Ccr also in the group 
of patients with impaired renal function at diagnosis. Univariate analysis 
nevertheless associated increased age with shortened renal survival. The 
discrepancy in the fi ndings regarding age is diffi cult to explain and needs 
to be studied more carefully. 
Differences in methodology makes the comparison of studies on prog-
nostic factors in IgAN diffi cult. Table12 shows the studies conducted on 
adult patients with normal renal function at diagnosis and multivariate 
analysis performed. It is diffi cult to compare the results of these studies 
because, for example, the outcome measures vary between the studies. 
Geographical variability in IgAN 
Long-term outcome of IgAN has been highly variable in previous studies, 
ranging from less than 10% to 43% of patients developing ESRF within 
10 years of diagnosis (Alamartine et al. 1991, Bartosik et al. 2001). There 
are several methodological biases explaining the variability as discussed 
in this thesis earlier. It has been suggested that there might be true geo-
graphic variability in the natural history of IgAN, resulting from genetic 
variations or environmental factors. 
In Study II the long-term natural history of a large cohort of patients 
with IgAN from four countries on three continents was described. The 
renal biopsy indications were variable. To overcome bias from differences 
in case mix, there are at least two methods that can be used in retro spect-
ive studies. The fi rst one is to study patients in different strictly defi ned 
clinical stages of the disease separately, as reported in Studies I and III. 
The second one is to use the slope of Ccr as an outcome variable as in 
Study III. It was concluded that the patients from Helsinki had milder clin-
ical fi ndings at baseline and better outcome than the patients from the 
other centres. The patients from Helsinki displayed signifi cantly slower 
deterioration independent of the other clinical parameters at baseline. 
Only in the subgroup of patients with Ccr < 75 ml / min no independent 
centre effect was observed. 
These fi ndings are most likely due to lead-time bias: the natural his-
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tory of IgAN in all the medical centres is the same, but the disease is 
detected at different stages in its course, due to different screening and 
renal biopsy policies. However, lead-time bias is not the only explanation, 
since the mean age of the patients was similar in all four centres. Study 
I shows that there is a substantial number of patients with normal renal 
function whose disease progresses very slowly or not at all. These patients 
would never be diagnosed in Glasgow or Toronto. Thus, it is possible that 
the IgAN patients diagnosed in these two centres are genetically more 
prone to progression of the renal disease than the patients diagnosed in 
Helsinki or Sydney. Variability in clinical features and outcome may also 
partly be due to environmental factors and medical management. 
Table 12 Comparison of studies on adult IgAN patients with normal renal function 
and multivariate analysis performed.
 Rauta et al. (I) Nieuwhof et al. (1998) To et al. (2000)
No. of patients 161 27 100
Sex (M / F, % of patients) 75 / 25 74 / 26 37 / 63
Mean age (years) 32 31 32
Hypertension 
 (% of patients) 33 0 19
History of episodes of 
 macroscopic hematuria 
 (% of patients) 38 37 
Duration of follow-up 
 (years) 10 11 10
Defi nition of normal 
 renal function Ccr ≥ 85ml / min s-crea < 120 umol / l s-crea < 130 umol / l
Defi nition of 20% impairment  Doubling of  ESRF
 progression of IgAN  of Ccr and  proteinuria and / or 
  Ccr < 85 ml / min  development 
   of hypertension 
   and / or s-crea 
   > 140 umol / l
Number of patients 
 classifi ed as progressors / 
 non-progressors 41 / 120 14 / 13 9 / 91
Factors found to affect  Higher number  Chronicity index > 3 Higher grades
 prognosis of IgAN  of urinary Presence of micro-  of glomerular
  erythrocytes  scopic hematuria  sclerosis
 Hypertension  instead of episodes
 Presence of   of macroscopic 
  arteriolosclerosis  hematuria
 Glomerular score ≥ 2
IgAN
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HSN
HSN is a rare disease in adults. Study III investigated the largest number 
of adult HSN patients diagnosed in a single medical centre. One third 
of our patients had isolated microscopic hematuria as an indication of 
renal biopsy. The Finnish patients also had fewer symptoms of the gastro-
intestinal tract or joints than the patients from France and Italy (Coppo 
et al. 1997, Coppo et al. 1999, Pillebout et al. 2002). These two fi ndings 
may be linked, and may be the result of renal biopsy policy. The clinical 
features, outcome and factors associated with progression are compared 
between the three studies on adult patients with biopsy-proven HSN in 
Table 13.
Most of the patients in Study III were women. There is no simple 
explan ation for this fi nding. It may result from the referral practice of 
patients with purpuric rash or the relatively small total number of pa-
tients diagnosed with HSN. The outcome of HSN was relatively good, and 
comparable to that of IgAN patients. The number of patients in Study III 
was not large enough to allow multivariate analysis. However, all three 
studies compared in Table 13 show that the degree of proteinuria is a 
strong predictor of progression in HSN.
Urinary excretion of IL-1β and IL-1ra in IgAN and HSN 
No other statistically signifi cant differences in clinical or histopathologic-
al fi ndings were observed between the groups of IgAN and HSN patients, 
except for of extra renal fi ndings in HSN. No previous studies have com-
pared histopathological and clinical fi ndings in adults with HSN or IgAN 
diagnosed in the same unit within the same time period. It should be 
noted, however, that a larger proportion of IgAN patients than HSN pa-
tients came to the study visit in 1997. There may, thus be some variation 
in the selection of the patients with the two diseases. Moreover, the HSN 
patients were followed up for a shorter time than the IgAN patients. The 
results of the comparison should therefore be considered with caution. 
We noted that HSN patients had higher urinary excretion of IL-1ra 
and IL-1ra / IL-1β ratio than IgAN patients. Several explanations may be 
offered. Concentrations of other cytokines contributing to the produc-
tion of IL-1ra may differ in HSN and IgAN. Furthermore, HSN is a small-
vessel vascu litis with perivascular accumulation of infl ammatory cells 
which have been shown to produce IL-1ra. There may also be genetically 
determined alterations in the production of IL-1ra. An association has 
been found between the IL1RN*2 allele and several infl ammatory dis-
eases (Cork et al. 1993, Mansfi eld et al. 1994, Blakemore et al. 1996). In 
some, like alopecia areata (Tarlow et al. 1994), lichen sclerosus (Clay et al. 
1994) and systemic lupus erythematosus (Blakemore et al. 1994), IL1RN*2 
Table 13 Comparison of studies on adult HSN patients. 
 Rauta et al. Pillebout Coppo et al. 
 (2002) (III) et al. (2002) (1997)
N  38 250 95
Follow-up (years) 6.1 14.8 4.9
Mean age (years) 38 50 41
Sex (M / F, % of patients) 47 / 53 63 / 27 60 / 40
Infection (% of patients) 29 32 23
Purpura (% of patients) 100 96 96
Gastrointestinal symptoms 
 (% of patients) 24 48 48
Arthralgia / arthritis (% of patients) 21 61 45
Urinary fi ndings preceding extra 
 renal symptoms (% of patients) 18 0.8 9
Episodes of macroscopic HU 
 (% of patients) 10 10 4
Microscopic HU (% of patients) 100 94 100
Proteinuria (% of patients) 71 96 96
Nephrotic range proteinuria 
 (% of patients) 26 28 30
Normal renal function 
 (% of patients) 66 * 68 ** 76 ***
Hypertension (% of patients) 42 36 21
ESRF (% of patients) 11 11 16
10 yr survival (% of patients) 91 82 75
Remission (% of patients) 35 20 33
Factors affecting outcome  dU-prot  dU-prot dU-prot
 in univariate analysis  > 1 g / 24 h  > 1 g / 24 h  > 1.5 g / 24 h
  Impaired renal Impaired renal
   function  function
  Macroscopic HU Hypertension
  Histopatho- 
   logical fi ndings
Factors affecting outcome  Impaired renal dU-prot
 in multivariate analysis   function   > 1.5 g / 24 h
  dU-prot 
   > 1 g / 24 h
  Histopatho- 
   logical fi ndings:
   · degree of inter-
   stitial fi brosis
   · percentages 
   of sclerotic 
   glomeruli
   · presence of 
   necrosis in 
   glomeruli
* Ccr ≥ 85 ml / min  ** Ccr > 50 ml / min  *** s-creatinine < 133 umol / l
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is an indication of the severity of the disease. Furthermore, in diabetes 
mellitus, patients with IL1RN*2 had an increased risk of diabetic com-
plications, especially nephropathy (Blakemore et al. 1996). IL1RN*2 was 
considered a genetic link between IgAN and HSN (Liu et al. 1997). An-
other study demonstrated a worse long-term survival rate among IgAN 
patients carrying IL1RN*2 (Shu et al. 2000). None of these studies have 
demonstrated the functional role of IL1RN*2 on serum or urine IL-1ra 
levels. Among healthy blood donors, IL1RN*2 carriers had signifi cantly 
higher plasma IL-1ra levels compared with non-carriers. However, the en-
hancing effect of IL1RN*2 on plasma IL-1ra level required the presence of 
specifi c IL-1β polymorphism or the absence of another, suggesting that 
the IL-1β gene participates in the regulation of IL-1ra production (Hurme 
and Santtila 1998). In yet another study a signifi cant association between 
the carriage of IL1RN*2 and severe renal involvement – nephrotic syn-
drome, and / or renal insuffi ciency and permanent renal involvement – was 
found in patients with HSP, but no association of this polymorphism was 
observed in patients with leucocytoclastic vasculitis restricted to the skin 
(Amoli et al. 2002). 
Histopathological changes in renal biopsy specimens from patients 
with IL-1ra / IL1β ratios above normal were signifi cantly milder than in 
renal biopsy specimens from patients with low or normal IL-1ra / IL1β 
ratios. This is in agreement with the fi nding that a balance between IL-
1ra and IL-1β is important in regulating infl ammatory processes. Whether 
this fi nding implicates that these patients have a better outcome remains 
to be resolved.
It was found that in both patients and controls, women had signifi -
cantly higher IL-1ra and IL-1β excretion levels. Lynch et al. (Lynch et 
al. 1994) reported a similar fi nding on urinary excretion of IL-1ra, but 
they did not observe any gender-related difference in the excretion of 
IL-1β. Recently Sadeghi et al. (2005a) reported fi ndings similar to ours 
in healthy individuals. They studied urine and plasma concentrations of 
IL-1β and IL-1ra, but the gender-related differences were found only in 
urine. Sadeghi et al. also measured the concentrations of several other 
cytokines in the IL-family, but all these concentrations were similar in 
men and women. In another study by the same authors, female trans-
plant recipients had signifi cantly higher IL-1ra urine levels than male 
transplant recipients (Sadeghi et al. 2005). The above fi nding may result 
from the effect of sex hormones (Rogers and Eastell 1998), particularly 
of estrogens (Neugarten et al. 2000). Whether the male predominance 
in IgAN and HSN, as in many other renal diseases, and the poorer out-
comes in men than in women with renal diseases are associated with the 
cap acity to produce IL-1ra, and especially a balance between IL-1ra and 
IL-1β, remains to be resolved.
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Summary and conclusions 
Large proportion of IgAN patients at the Division of Nephrology, Helsinki 
University Hospital, had normal renal function and mild histo patho logical 
fi ndings at the time of diagnosis. The results provide new insight into 
how these factors vary with the stage of IgAN and with the level of renal 
function on diagnosis. Four factors, hypertension, urinary erythrocytes, 
arteriolosclerosis and glomerular score, were found to independently 
predicted progression in mild forms of IgAN. A mathematical model for 
predicting the outcome in adult IgAN patients with normal renal func-
tion on diagnosis was formed. Our study showed that factors associated 
with outcome can be identifi ed even in mild cases of IgAN, thus indi-
cating that early diagnosis of this disease is desirable. A mathematical 
model of this kind would be useful in identifying patients in whom early 
therapeutic intervention could be effective. (I) 
The results demonstrated that there is geographic variability in renal 
survival and the slope of Ccr in patients with IgAN. When age, Ccr, UP 
and MAP are taken into account, this study suggests that the variability 
relates mostly to lead-time bias and the inclusion of milder cases in med-
ical centers with apparent good outcome. (II) 
Similarly to the fi ndings on IgAN, the clinical and especially histopatho-
logical fi ndings in adult HSN were milder than in other previous studies. 
HSN has been considered to be a systemic form of IgAN. In 18% of the 
patients urinary abnormalities were detected prior to purpura, support-
ing overlapping of IgAN and HSN. HSN is rare in adults and its outcome 
is unpredictable. A level of proteinuria more than 0.4 g / 24 h was the 
only factor signifi cantly related to the progression of IgAN. In a small 
group of patients with normal renal function at the time of diagnosis, 
the presence of hypertension and the level of Ccr were found to predict 
outcome. (III)
We observed that the excretion of cytokine IL-1ra in the urine of IgAN 
patients was decreased, as compared with HSN patients and healthy con-
trols. Patients with a high IL-1ra / IL-1β ratio had milder histopathologi-
cal changes in renal biopsy than patients with a low / normal IL-1ra / IL-1β 
ratio. We also found that the excretion of IL-1β, and especially IL-1ra, was 
signifi cantly higher in women.
Summary and conclusions
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